Professional Documents
Culture Documents
doi:10.1093/eurheartj/ehv320
2015ESCGuidelinesforthemanagement
ofacutecoronarysyndromesinpatients
presentingwithoutpersistentST-segment
elevation
Task Force for the Management of Acute Coronary Syndromes
in Patients Presenting without Persistent ST-Segment Elevation
of the European Society of Cardiology (ESC)
Authors/Task Force Members: Marco Rof* (Chairperson) (Switzerland),
Carlo Patrono* (Co-Chairperson) (Italy), Jean-Philippe Collet (France),
Christian Mueller (Switzerland), Marco Valgimigli (The Netherlands),
Felicita Andreotti (Italy), Jeroen J. Bax (The Netherlands), Michael A. Borger
(Germany), Carlos Brotons (Spain), Derek P. Chew (Australia), Baris Gencer
(Switzerland), Gerd Hasenfuss (Germany), Keld Kjeldsen (Denmark),
Patrizio Lancellotti (Belgium), Ulf Landmesser (Germany), Julinda Mehilli (Germany),
Debabrata Mukherjee (USA), Robert F. Storey (UK), and Stephan Windecker
(Switzerland)
Document Reviewers: Helmut Baumgartner (CPG Review Coordinator) (Germany), Oliver Gaemperli (CPG Review
Coordinator) (Switzerland), Stephan Achenbach (Germany), Stefan Agewall (Norway), Lina Badimon (Spain),
Colin Baigent (UK), He ctor Bueno (Spain), Raffaele Bugiardini (Italy), Scipione Carerj (Italy), Filip Casselman
(Belgium), Thomas Cuisset (France), etin Erol (Turkey), Donna Fitzsimons (UK), Martin Halle (Germany),
Christian Hamm (Germany), David Hildick-Smith (UK), Kurt Huber (Austria), Efstathios Iliodromitis (Greece),
Stefan James (Sweden), Basil S. Lewis (Israel), Gregory Y. H. Lip (UK), Massimo F. Piepoli (Italy), Dimitrios Richter
(Greece), Thomas Rosemann (Switzerland), Udo Sechtem (Germany), Ph. Gabriel Steg (France), Christian Vrints
(Belgium), and Jose Luis Zamorano (Spain)
The disclosure forms of all experts involved in the development of these guidelines are available on the ESC website
http://www.escardio.org/guidelines
-----------------------------------------------------------------------------------------------------------------
-------------------------------------
Keywords Acute cardiac care Acute coronary syndromes Angioplasty Anticoagulation Apixaban Aspirin
Atherothrombosis Beta-blockers Bivalirudin Bypass surgery Cangrelor Chest pain unit
Clopidogrel Dabigatran Diabetes Early invasive strategy Enoxaparin European Society of
Cardiology Fondaparinux Glycoprotein IIb/IIIa inhibitors Guidelines Heparin High-sensitivity
troponin Myocardial ischaemia Nitrates Non-ST-elevationmyocardial infarction Plateletinhibition
Prasugrel Recommendations Revascularization Rhythmmonitoring Rivaroxaban Statin Stent
Ticagrelor Unstable angina Vorapaxar
5.9.1.5 Mineralocorticoid receptor antagonist therapy . 304 CKD chronic kidney disease
5.9.1.6 Antihypertensive therapy . . . . . . . . . . . . . . . 304 CK-MB
creatine kinase myocardial band
5.9.1.7 Glucose-lowering therapy in diabetic patients . . 304
COX
cyclooxygenase
5.9.2 Lifestyle changes and cardiac rehabilitation . . . . . . . 305
5.9.3 Recommendations for long-term management after CMR
cardiac magnetic resonance
non-ST-elevation acute coronary syndromes . . . . . . . . . 305 CPG Committee for Practice Guidelines
6. Performance measures . . . . . . . . . . . . . . . . . . . . . . . . . . 305 CREDO
Clopidogrel for the Reduction of Events
During Observation
7. Summary of management strategy . . . . . . . . . . . . . . . . . . . 306
8. Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 307 CRUSADE
Can Rapid risk stratication of Unstable an-
9. To do and not to do messages from the guidelines . . . . . . . . 308 gina patients Suppress ADverse outcomes
10. Web addenda and companion documents. . . . . . . . . . . . . 309 with Early implementation of the ACC/AHA
11. Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . 309
guidelines
12. Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309
CT
computed tomography
13. References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309
CURE Clopidogrel in Unstable Angina to Prevent
Recurrent Events
CURRENT-OASIS
7
Clopidogrel and Aspirin Optimal Dose Usage
Abbreviations and acronyms to Reduce Recurrent EventsSeventhOrgan-
ization to Assess Strategies in Ischaemic
Syndromes
ACC American College of Cardiology CV cardiovascular
ACCOAST Comparison of Prasugrel at the Time of CYP cytochrome P450
Percutaneous Coronary Intervention or as DAPT dual(oral) antiplatelet therapy
Pretreatment at the Time of Diagnosis in DES drug-eluting stent
Patients with Non-ST Elevation Myocardial EARLY-ACS Early Glycoprotein IIb/IIIa Inhibition in
Infarction Non-ST-Segment Elevation Acute Coronary
ACE angiotensin-converting enzyme Syndrome
ACS acute coronary syndromes ECG electrocardiogram
ACT activated clotting time eGFR estimated glomerular ltration rate
ACTION Acute Coronary Treatment and Intervention EMA European Medicines Agency
Outcomes Network ESC European Society of Cardiology
ACUITY Acute Catheterization and Urgent Interven- FDA Food and Drug Administration
tion Triage strategY FFR fractional ow reserve
ADAPT-DES AssessmentofDualAntiPlateletTherapywith FREEDOM Future Revascularization Evaluation in
Drug-Eluting Stents Patients with Diabetes Mellitus: Optimal
ADP adenosine diphosphate Management of Multivessel Disease
AHA American Heart Association GPIIb/IIIa glycoprotein IIb/IIIa
APPRAISE Apixaban for Prevention of Acute IschaemicGRACE 2.0 Global Registry of Acute Coronary Events 2.0
Events GUSTO Global Utilization of Streptokinase and TPA
aPTT activated partial thromboplastin time for Occluded Arteries
ARB angiotensin receptor blocker GWTG Get With The Guidelines
ATLAS ACS HAS-BLED hypertension, abnormal renal and liver func-
2-TIMI 51 tion (1 point each), stroke, bleeding history
or predisposition, labile INR, elderly (.65
years), drugs and alcohol (1 point each)
HIT heparin-induced thrombocytopenia
Anti-Xa Therapy to Lower Cardiovascular
HORIZONS Harmonizing Outcomes with Revasculariza-
Events in Addition to Aspirin With or With-
tiON and Stents in Acute Myocardial Infarction
out Thienopyridine Therapy in Subjects with
HR hazard ratio
Acute Coronary SyndromeThrombolysis
IABP-Shock II Intra-Aortic Balloon Pump in Cardiogenic
in Myocardial Infarction 51
Shock II
ATP adenosine triphosphate
IMPROVE-IT IMProved Reduction of Outcomes: Vytorin
BARC Bleeding Academic Research Consortium
Efcacy International Trial
BMS bare-metal stent
INR international normalized ratio
CABG coronary artery bypass graft
ISAR-CLOSURE Instrumental Sealing of ARterial puncture
CAD coronary artery disease
siteCLOSURE device versus manual
CHA2DS2-VASc Cardiac failure, Hypertension, Age e75
compression
(2 points), Diabetes, Stroke (2 points)
ISAR-REACT Intracoronary stenting and Antithrombotic
Vascular disease, Age 6574, Sex category
RegimenRapid Early Action for Coronary
CHAMPION Cangrelor versus Standard Therapy to
Treatment
Achieve Optimal Management of Platelet
Inhibition
CI condence interval
CK creatine kinase
ESC Guidelines 271
May be considered
Class IIb
favourby
established ofevidence/opinion.
usefulness/efficacy. Is not
Class III Evidence or general agreement recommended
that the given treatment or
Usefulness/efficacy
procedure is
is not useful/effective,
less well
and in some cases may be harmful.
riskbenetratio.Estimatesofexpectedhealthoutcomesforlarger
Table 2 Levels of evidence
populations were included, where data exist. The level of evidence
and the strength of the recommendation of particular management
optionswereweighedandgradedaccordingto predenedscales,asLevel of Data derived from multiple
outlined in Tables 1 and 2. evidenc
randomized
The experts of the writing and reviewing panels provided declar- eA clinical trials or meta-analyses.
Data derived from a single
ationofinterestformsforallrelationshipsthatmightbeperceivedas
randomized
real or potential sources of conicts of interest. These forms were Level of
clinical trial or large non-randomized
compiled into one le and can be found on the ESC website (http:// evidence B
studies.
www.escardio.org/guidelines). Any changes in declarations of Consensus of opinion of the
interest that arise during the writing period must be notied to Level of experts and/
the ESC and updated. The Task Force received its entire nancial or small studies, retrospective
evidence Cstudies,
support fromthe ESC without any involvementfrom the healthcare
registries.
industry.
TheESCCPGsupervisesandcoordinatesthepreparationofnew
Guidelinesproducedbytaskforces,expertgroupsorconsensuspa-
nels. The Committee is also responsible for the endorsementThe National
pro- Societies of the ESC are encouraged to endorse,
translate and implement all ESC Guidelines. Implementation pro-
cess of these Guidelines. The ESC Guidelines undergo extensive
review by the CPG and external experts. After appropriate grammes
revi- are needed because it has been shown that the
outcome
sions the Guidelines are approved by all the experts involved in
the Task Force. The nalized document is approved by the of CPG
disease may be favourably inuenced by the thorough applica-
tion
for publication in the European Heart Journal. The Guidelines of clinical recommendations.
were developed after careful consideration of the scientic Surveysandregistriesareneededtoverifythatreal-lifedailyprac-
and medical knowledge and the evidence available at the ticetime
is in of
keeping with what is recommended in the guidelines,
their dating. thus
The task of developing ESC Guidelines covers not onlycompleting the loop between clinical research, writing of
guidelines,
integration of the most recent research, but also the creation of
educational tools and implementation programmes for disseminating
the recom- them and implementing them into clinical practice.
mendations. To implement the guidelines, condensed pocket Health professionals are encouraged to take the ESC Guidelines
fully into
guidelines versions, summary slides, booklets with essential mes- account when exercising their clinical judgment, as well
as
sages, summary cards for non-specialists and an electronic version
for digital applications (smartphones, etc.) are produced. inthedeterminationandtheimplementationofpreventive,diagnos-
These
tic or therapeutic
versions are abridged and thus, if needed, one should always refer medical strategies. However, the ESC
Guidelines
to the full text version which is freely available on the ESC website.
do not override in any way whatsoever the individual
responsibility
of health professionals to make appropriate and accurate
decisions
in consideration of each patients health condition and in consult-
ationwiththatpatientandthepatientscaregiverwhereappropriate
and/or necessary. It is also the health professionals responsibility
to
verifytherulesandregulationsapplicabletodrugsanddevicesatthe
time of prescription.
ESC Guidelines 273
1. Presentation
2.
ECG
3.
Troponin
Figure 1 Initial assessment of patients with suspected acute coronary syndromes. The initial assessment is based on the integration of low-
likelihoodand/orhigh-likelihoodfeaturesderivedfromclinical presentation(i.e.,symptoms,vital signs), 12-leadECG,andcardiactroponin. Thepro-
portion of the nal diagnoses derived from the integration of these parameters is visualized by the size of the respective boxes. Other cardiac
includes,amongother,myocarditis,Tako-Tsubocardiomyopathy,ortachyarrhythmias.Non-cardiacreferstothoracicdiseasessuchaspneumonia
orpneumothorax.Cardiactroponinshouldbeinterpretedasaquantitativemarker:thehigherthelevel,thehigherthelikelihoodforthepresenceof
myocardial infarction. In patients presenting with cardiac arrest or haemodynamic instability of presumed cardiovascular origin,
echocardiography
should be performed/interpreted by trained physicians immediately following a 12-lead ECG. If the initial evaluation suggests aortic dissection or
pulmonary embolism, D-dimers and multi-detector computed tomography angiography are recommended according to dedicated
algorithms.42,43
ESC Guidelines 275
Table 3 Clinical implications of high-sensitivity Table 4 Conditions other than acute myocardial
cardiac troponin assays infarction type 1 associated with cardiac troponin
elevation
Compared with standard cardiac troponin assays, high-sensitivity
assays:
" Have higher negative predictive value for acute MI. Tachyarrhythmias
" Reduce the troponin-blind interval leading to earlier detection of acute MI. Heart failure
" Result in a ~4% absolute and ~20% relative increase in the detection of Hypertensive emergencies
type 1 MI and a Critical illness (e.g. shock/ sepsis/ burns)
corresponding decrease in the diagnosis of unstable angina. Myocarditisa
" Are associated with a 2-fold increase in the detection of type 2 MI. Tako-Tsubo cardiomyopathy
Levels of high-sensitivity cardiac troponin should be interpreted Structural heart disease (e.g. aortic stenosis)
as quantitative Aortic dissection
markers of cardiomyocyte damage (i.e. the higher the level, the Pulmonary embolism, pulmonary hypertension
greater the Renal dysfunction and associated cardiac disease
likelihood of MI):
" Elevations beyond 5-fold the upper reference limit have high (>90%) Acute neurological event (e.g. stroke or subarachnoid
positive predictive
haemorrhage)
value for acute type 1 MI. Cardiac contusion or cardiac procedures (CABG, PCI, ablation,
" Elevations up to 3-fold the upper reference limit have only limited
pacing,
Coronarycardioversion,
spasm or
(5060%) positive endomyocardial biopsy)
predictive value for acute MI and may be associated with a broad
Hypo- and hyperthyroidism
spectrum of conditions.
" It is common to detect circulating levels of cardiac troponin in healthy
individuals.
Rising and/or falling cardiac troponin levels differentiate acute
from chronic
cardiomyocyte damage (the more pronounced the change, the
higher the
likelihood of acute MI).
obtain it within 10 min of the patients arrival in the emergency venoms)
Extreme endurance efforts
room Rhabdomyolysis
or,ideally,atrstcontactwithemergencymedicalservicesinthepre-
MI myocardial infarction.
hospital setting and to have it immediately interpreted by a
qualied
Bold = most frequent conditions; CABG coronaryartery bypass
physician.28 While the ECG in the setting of NSTE-ACS may be nor- PCI
surgery;
mal in more than one-third of patients, characteristic percutaneous coronary intervention.
abnormalities aincludes myocardial extension of endocarditis or pericarditis.
includeSTdepression,transientSTelevationandT-wavechanges.the vast1,18
majority of cardiac troponin assays run on automated
If the standard leads are inconclusive and the patient plat-
has signs or
symptoms suggestive of ongoing myocardial ischaemia, formsandaresensitive(i.e.allowfordetectionofcardiactroponinin
additional 2050% of healthy individuals) or high-sensitivity (detection in
leads should be recorded; left circumex artery occlusion or right
5090% of healthy individuals) assays. High-sensitivity assays are
ventricular MI may be detected only in V7V9 and V3R and V4R, re-
recommendedoverlesssensitiveones. 2,6,8Themajorityofcurrently
spectively.2 In patients with suggestive signs and symptoms, the
used point-of-care assays cannot be considered sensitive or high-
nding of persistent STelevation indicates STEMI, whichsensitivity
mandatesassays.8,35 Therefore the obvious advantage of
immediate reperfusion.1 Comparison with previous tracings is
point-of-care tests, namely the shorter turnaround time, is
valuable, particularly in patients with pre-existing ECGcounter-
abnormal-
ities. It is recommended to obtain additional 12-lead ECGs in the
balanced by lower sensitivity, lower diagnostic accuracy and
case of persistent or recurrent symptoms or diagnostic uncer-
lower
tainty. In patients with bundle branch block or paced rhythm,
negative predictive value. Overall, automated assays have been
ECG is of no help for the diagnosis of NSTE-ACS. morethoroughlyevaluatedascomparedwithpoint-of-caretests.2,6,8
As these techniques continue to improve and performance
charac-
3.3.2 Biomarkers teristics are bothassayandhospital dependent,norecommendation
Biomarkers complement clinical assessment and 12-lead regarding
ECG inthe site of measurement (central laboratory vs.
the bedside)
diagnosis, risk straticationand treatment ofpatients withsuspected
can be given.2,6,8,38 Data from large multicentre studies have
NSTE-ACS. Measurement of a biomarker of cardiomyocyte consist-
injury,
preferably high-sensitivity cardiac troponin, is mandatoryentlyinshown
all that sensitive and high-sensitivity cardiac troponin
pa- as-
tients with suspected NSTE-ACS.2,6,8 Cardiac troponinssays are more
increase diagnostic accuracy for MI at the time of
sensitive and specic markers of cardiomyocyte injury presentation
than
creatine ascomparedwithconventionalassays,especiallyinpatientspresent-
kinase (CK), its MB isoenzyme (CK-MB) and myoglobin.ing 6 Ifearly
the clin-
after chest pain onset, and allow for a more rapid rule-in
ical presentation is compatible with myocardial ischaemia,and rule-out
then a of MI (see section 3.3.3 and Table 3).2,6,8,2934
dy- Inmostpatientswithrenaldysfunction,elevationsincardiactropo-
namic elevation of cardiac troponin above the 99th percentile
nin should of not be primarilyattributed to impaired clearance and
healthy individuals indicates MI.2 In patients with MI, levels
con- of
cardiac sidered harmless, as cardiac conditions such as chronic coronary
troponin rise rapidly(i.e. usually within 1 h if using high-
or
sensitivityas- hypertensive heart disease seem to be the most important
says) after symptom onset and remain elevated for a contribu-
variable
period tor to troponin elevation in this setting.41 Other life-threatening
oftime(usuallyseveraldays).2,6Advancesintechnologyhaveledtoa
con-
renement in cardiac troponin assays and have improved ditions
the presenting with chest pain, such as aortic dissection and
ability pulmonary embolism, may also result in elevated troponin levels
to detect and quantify cardiomyocyte injury.2,6,8,10,2937and
In Europe,
should be considered as differential diagnoses (Table 4).
H
Acute Chest
Pain
hs-cTn
hs-cTn <ULN hs-cTn >ULN hs-cTn
<ULN >ULN
Pain
Pain Pain
Pain
>6h
>6h <6h
<6h
Re-test hs-
cTn: 3h
hs-cTn
hs-cTnno
no change
changeaa
hs-cTn
hs-cTnno
no
change
change (1
(1value
value>>
change
change
ULN)
ULN)
Painfree,
Painfree,GRACE
GRACE<140,
<140,
differential
differentialdiagnoses
diagnosesexcluded
excluded Work-up
Work-updifferential
differential
diagnoses
diagnoses
Discharge/Stress
Discharge/Stress Invasive
Invasive
testing
testing management
management
GRACE = Global Registry of Acute Coronary Events score; hs-cTn = high sensitivity cardiac troponin; ULN = upper limit of normal, 99th
percentile of healthy controls.
a
Figure 2 0 h/3 h rule-out algorithm of non-ST-elevation acute coronary syndromes using high-sensitivity cardiac troponin assays.
TheuseoftheCRUSADEscorem
aybe
5.Treatment
IIb B 106,
considered in patients
107
undergoing 5.1Pharmacological treatment of
coronary angiography to
Imaging
quantify ischaemia
In patients
bleeding with no recurrence of
risk. 5.1.1 General supportive measures
chest pain, normal ECG ndings and The goal of pharmacological anti-ischaemic therapy is to decrease
normal levels of cardiac troponin myocardial oxygen demand (secondary to a decrease in heart rate,
(preferably high-sensitivity), but
64,74, blood pressure, preload or myocardial contractility) or to increase
suspected ACS, a non-invasive stress
I A 113, myocardial oxygen supply (by administration of oxygen or through
test (preferably with imaging) for
114 coronary vasodilation). If, following treatment, the patient does not
inducible ischaemia is recommended
before deciding on an invasive rapidly become free of ischaemic signs or symptoms, immediate
strategy. cor-
onary angiography is recommended independently of ECG ndings
Echocardiography is
andcardiactroponinlevels.WhiledatainNSTE-ACSarelacking,aran-
recommended to I domized comparison of oxygen vs. air administration in 441
C
evaluate regional and global LV normox-
function and to rule in or rule out aemic patients with STEMI showed no benet and possibly harm
differential diagnoses.d associated with oxygen administration. Oxygen should be adminis-
MDCT coronary angiography should tered when blood oxygen saturation is ,90% or if the patient is in
be considered as an alternative to re-
invasive angiography to exclude ACS spiratory distress.115 In patients whose ischaemic symptoms are not
IIa A 80
when there is a low to intermediate relieved by nitrates and beta-blockers, opiate administration is
likelihood of CAD and when cardiac
reason-
troponin and/or ECG are
inconclusive. ablewhilewaitingforimmediatecoronaryangiography,withthecaveat
Monitoring
thatmorphinemayslowintestinalabsorptionoforalplateletinhibitors.
Continuous rhythm monitoring
is
recommended untilI theC 101 5.1.2 Nitrates
diagnosis
Intravenous nitrates are more effective than sublingual nitrates
of NSTEMI is established or
ruled
with
out.
It is recommended to admit NSTEMI
regard to symptom relief and regression of ST depression. Under
patients to a monitored unit. I C 99,100 careful blood pressure monitoring, the dose should be titrated up-
wardsuntilsymptomsarerelieved,andinhypertensivepatientsuntil
Rhythm monitoringIIaup to
blood pressure is normalized, unless side effects (notably headache
C 24 h or PCI
(whichever comes rst) should be or hypotension) occur. Beyond symptom control, there is no indi-
considered in NSTEMI patients at low cation for nitrate treatment.116 In patients with recent intake of a
risk for cardiac arrhythmias.e phosphodiesterase type 5 inhibitor (i.e. within 24 h for sildenal
Rhythm monitoring for .24 h should or vardenal and 48 h for tadalal), nitrates should not be adminis-
IIa C patients at
be considered in NSTEMI tered due to the risk of severe hypotension.117
intermediate to high-risk for cardiac
arrhythmias.f
5.1.3 Beta-blockers
Intheabsenceofsignsorsymptomsof
Beta-blockers competitively inhibit the myocardial effects of circu-
ongoing ischaemia, rhythm monitoring
in unstable angina may be considered lating catecholamines and reduce myocardial oxygen consumption
IIbof C
in selected patients (e.g. suspicion by lowering heart rate, blood pressure and myocardial contractility.
coronary spasm or associated The evidence for the benecial effects of beta-blockers in
symptoms suggestive of arrhythmic NSTE-ACS is derived from a meta-analysis of 27 earlystudiesshow-
events). ing that beta-blocker treatment was associated with a signicant
13% relative risk reduction (RRR) of mortality in the rst week fol-
ACS acute coronary syndromes; CAD coronary artery disease; lowingMI.
ECG 118Inaddition,alatermeta-analysiscomprising73396pa-
electrocardiogram; LV left ventricular; MDCT multidetector tients with ACS showed an 8% RRR (P 0.04) for in-hospital
computed
tomography; NSTEMI non-ST-elevation myocardial infarction;mortality
PCI associated with beta-blockade, with no increase in cardio-
percutaneous coronary intervention. 0 h time of rst blood test; 1 h, 3 h
1
genic shock. 119 A registry study of 21 822 NSTEMI patients found
or 3 h after the rst blood test. that in patients at risk of developing cardiogenic shock (i.e. age
aClass of recommendation. .70 years, heart rate .110 beats/min, systolic blood pressure
bLevel of evidence.
,120 mmHg) the observed shock or death ratewas signicantly in-
cReferences supporting level of evidence.
creased in patients receiving beta-blockers within 24 h of hospital
dDoes not apply to patients discharged the same day in whom NSTEMI has
been admission.120 Therefore early administration of beta-blockers
ruled out. should be avoided in these patients if the ventricular function is un-
eIf none of the following criteria: haemodynamically unstable, major
known. Beta-blockers should not be administered in patients with
arrhythmias,
symptoms possibly related to coronary vasospasm or cocaine use,
left ventricular ejection fraction ,40%, failed reperfusion, additional critical
coronary stenoses of major vessels or complications related toas they might favour spasm by leaving alpha-mediated
percutaneous vasoconstric-
revascularization. tion unopposed by beta-mediated vasodilation.
f If one or more of the above criteria are present.
282 ESC Guidelines
ADP = adenosine diphosphate; AT = antithrombin; GP = glycoprotein; LMWH = low molecular weight heparin; Tx = thromboxane;
UFH = Unfractionated heparin. Vorapaxar is a protease-activated receptor 1 (PAR1) blocker.
Figure 4 Antithrombotic drugs for non-ST-elevation acute coronary syndromes. The gure depicts the targets of available antithrombotic
drugs that can be used to inhibit blood coagulation and platelet aggregation during and after thrombus formation.
5.2.2.3 Ticagrelor drugs metabolized through CYP3A, such as simvastatin, while mod-
Ticagrelorisanoral,reversiblybindingP2Y12inhibitorwithaplasma
erateCYP3Ainhibitors,suchasdiltiazem,increaseticagrelorplasma
half-life of 612 h. Ticagrelor also inhibits adenosine reuptake
levels and might delay the offset of effect. In the PLATelet inhibition
via and patient Outcomes (PLATO) trial, 18 624 patients with
equilabrative nucleosidetransporter 1 (ENT1) (Table8). moderate- to high-risk NSTE-ACS (planned for either conservative
Likeprasu- or invasive management) or STEMI were randomized to either clo-
grel, ticagrelorhas amorerapidandconsistent onset ofaction
pidogrel 75 mg/day, with a loading dose of 300600 mg, or
com-
pared with clopidogrel, as well as a faster offset of action with
more
rapid recovery of platelet function.152 Ticagrelor increases
levels of
284 ESC Guidelines
ADP adenosine diphosphate; ATP adenosine triphosphate; CKD chronic kidney disease; eGFR estimated glomerular ltration rate.
a50% inhibition of ADP-induced platelet aggregation.
bOnset of effect may be delayed if intestinal absorption is delayed (e.g. by opiate).
cShortening may be considered if indicated by platelet function tests and low bleeding risk.
dAffecting the response to platelet transfusion.
eThe distribution phase half-life is reported since it most likely reects duration of clinically-relevant plasma levels, while the corresponding elimination phase
half-life is
approximately 7 hours.
5.2.3 Timing of P2Y12 inhibitor administration In patients undergoing elective non-cardiac surgery, ticagrelor
Initiation of P2Y12 inhibitors soon after the diagnosisand
of NSTE-ACS
clopidogrelshould be discontinued 5 days beforesurgery, while
irrespectiveof management strategy has been recommended.
the interval162,163
should be increased to 7 days in patients on prasugrel,
This implies pretreatment, dened as P2Y12 inhibitor unless
administration
the patient is at high risk of stent thrombosis. 179 In the latter
before coronary angiography, in patients scheduledcase, for ana invasive
multidisciplinary decision is required to determine the best
approach.SubsequentlytheresultsoftheonlyRCTonP2Y strategy.
12inhibi- Longer discontinuation times (e.g. 7 days for ticagrelor
tor pretreatment in NSTE-ACS, the Comparison of Prasugrel
and 10 days at thefor clopidogrel or prasugrel) may be appropriate for
Time of Percutaneous Coronary Intervention or as Pretreatment
surgery at extremeat risk of bleeding (e.g. some types of neurosur-
the Time of Diagnosis in Patients with Non-ST Elevationgery).Myocardial
For NSTE-ACS patients, the risk of bleeds related to surgery
Infarction (ACCOAST) trial, were published. 164 The ACCOAST
must be balanced against the risk of recurrent ischaemic events
study compared pretreatment with prasugrel 30 mgrelated and a further
to discontinuation of therapy. The type of surgery, the is-
30 mg dose prior to PCI with a regimen of prasugrelchaemic
60 mg after risk and extent of CAD, the time since the acute episode
diagnostic angiography but prior to PCI among 4033and, patients
for patients
with who have undergone PCI, the time since the pro-
NSTEMI scheduled for early invasive strategy. The median
cedure duration
and the type of stent implanted are key elements of the dis-
ofpretreatmentwas4.3 h.Sixty-ninepercentofthepatientsunder-
cussion. Selected patients who require non-cardiac surgery after
went PCI, 6% required surgical revascularization and recently
the remainder
implanted stents may benet from bridging therapy with
were treated conservatively.164 At 7 days, patients randomized
small molecule to GPIIb/IIIa inhibitors (i.e. tiroban or eptibatide)
thepretreatmentarmexperiencednoreductionintheprimaryend-
after discontinuation of the P2Y12 inhibitor, while cangrelor has so
point (i.e. CV death, recurrent MI, stroke, urgent revascularization
far been tested as bridging therapy to CABG.181,182 In patients on
and bailout use of GPIIb/IIIa inhibitors) [HR 1.02 (95%DAPTCI 0.84,
following an episode of NSTE-ACS that was treated conser-
1.25), P 0.81], and no benets emerged at 30 days. vatively,
164 TIMI the
major
P2Y12 inhibitor may be discontinued. In surgical proce-
bleeds were signicantly increased in the pretreatment duresgroup
withatlow to moderate bleeding risk, surgeons should be
7 days [pretreatment 2.6% vs. no pretreatment 1.4%; encouraged
HR 1.90, to operate on patients on DAPT. Adherence to
(95% CI 1.19, 3.02), P 0.006]. Arguments for andDAPT againstshould be improved through education of patients, relatives
pretreat- and physicians in order to prevent avoidable CV events.
ment with P2Y12 inhibitors in NSTE-ACS patients have been dis-
cussed extensively and the topic remains controversial.165,166 As
the optimal timing of ticagrelor or clopidogrel administration
5.2.6 Durationin of dual antiplatelet therapy
NSTE-ACS patients scheduled for an invasive strategy In patients been
has not with NSTE-ACS, DAPT with aspirin and clopidogrel has
adequately investigated, no recommendation for orbeen againstrecommended for 1 yearoveraspirin alone, irrespectiveof re-
pretreat- vascularizationstrategyandstenttype,accordingtotheClopidogrel
ment with these agents can be formulated. Based on in the ACCOAST
Unstable Angina to Prevent Recurrent Events (CURE) study,
results, pretreatment with prasugrel is not recommended.
while the In TRITON-TIMI 38 and PLATO studies have demonstrated
NSTE-ACS patients planned for conservative management, P2Y12 in-
the superiority of a prasugrel- and ticagrelor-based regimen, re-
hibition (preferably with ticagrelor) is recommended, in the
spectively,overaclopidogrel-basedone.138,148,153A1-yearduration
absence of DAPT with clopidogrel was associated with a 26.9% RRR of
of contraindications, as soon as the diagnosis is conrmed.
death, MI or stroke (8.6% vs. 11.8%; 95% CI 3.9, 44.4; P 0.02)
vs. 1-month DAPT in the Clopidogrel for the Reduction of Events
5.2.4 Monitoring of P2Y12 inhibitors (see Web addenda) During Observation (CREDO) trial, which enrolled 2116 pa-
5.2.5 Premature discontinuation of oral antiplatelet tients.183 The study population comprised patients with stable
therapy CAD and low-risk NSTE-ACS undergoing PCI (each 50%), and no
Withdrawal of oral antiplatelet therapy may lead to interaction
an increased between ACS status and DAPT was observed.
risk Evidence to support the extension of DAPT after DES beyond
of recurrent events, particularly when the recommended 1 yearcourse of
in NSTE-ACS patients is limited (Table 9, see Web addenda).
therapy has not yet been completed.176178 Interruption of DAPT
Table 9 (see Web addenda) Main features of published
soon after stent implantation increases the risk of stent thrombosis,
randomized studies investigating various durations of
especially within the rst month after cessation.178 While
dual discontinu-
antiplatelet therapy following percutaneous coronary
ationof DAPT prior to cardiac surgery is discussed inintervention
sections (PCI)
5.6.6.1 The DAPT trial randomized patients who did not experience ad-
Webaddendaand5.6.6.2,inthecaseofanon-cardiacsurgicalproced-
verse events in the rst year after PCI to an additional 18 months of
ure that cannot be postponed, a minimum of 1 and thienopyridine
3 months DAPT(clopidogrel/prasugrel) or placebo. 184 Continued
for bare-metal stents (BMSs) and new-generation DESs, treatment with thienopyridine, as compared with placebo, reduced
respectively, the rates of stent thrombosis [0.4% vs. 1.4%; HR 0.29 (95% CI 0.17,
mightbeacceptable.179Inthissetting,surgeryshouldbeperformedin
0.48), P , 0.001] and majoradverse cardiovascularand cerebrovas-
hospitals having continuous catheterization laboratory availability,
cularevents [4.3% vs. 5.9%; HR 0.71 (95%CI 0.59, 0.85), P , 0.001].
so The rate of MI was lower with thienopyridine treatment than with
astotreatpatientsimmediatelyincaseofperioperativeMI. 179Ifinter-
placebo (2.1% vs. 4.1%; HR 0.47, P , 0.001). The rate of death from
ruption of DAPT becomes mandatory because of urgent high-risk
any cause was 2.0% in the group that continued thienopyridine
surgery(e.g.neurosurgery)orinthecaseofamajorbleedthatcannot
be controlled by local treatment, no alternative therapy can be pro-
posedasasubstitutetoDAPTtopreventstentthrombosis.Lowmo-
lecularweightheparin(LMWH)hasbeenadvocated,buttheproof of
efcacy for this indication is lacking.180 Whenever possible, aspirin
should be continued because early discontinuation of both
antiplate-
let drugs will further increase the risk of stent thrombosis.
286 ESC Guidelines
therapyand1.5%in theplacebogroup[HR1.36(95%CI1.00,1.85), appeared consistent among patients receiving and not receiving
P 0.05]. The rate of moderate or severe bleeding was increased
GPIIb/IIIa inhibitors, the efcacy and safety of GPIIb/IIIa inhibitors
with continued thienopyridine treatment [2.5% vs. 1.6%; on HRtop1.61
of these P2Y12 inhibitors have not been prospectively ad-
(95% CI 1.21, 2.16), P 0.001].184 A meta-analysis including
dressed.153,197 In patients treated with prasugrel or ticagrelor,
32 287 patients enrolled in 10 RCTs compared differentGPIIb/IIIa
DAPT inhibitors should be limited to bailout situations or
durations.185 Nearly 50% of the patients had stable CAD. Studies complications during PCI. Dosing in patients with
thrombotic
werestratiedaccordingtotheDAPTdurationinthecontrolgroup impaired renal function is reported in Table 10. Additional
in order to avoid having 12-month DAPT duration included in both
informa-
study arms. As a consequence, it allowed comparison of tionoutcomes
on GPIIb/IIIa inhibitors may be found in sections 5.2.7.1
of either short-term or extended (i.e. beyond 12 months) DAPT while GPIIb/IIIa inhibitor-related thrombocytopenia is
5.2.7.3,
duration vs. 12-month therapy. Compared with 12-month DAPT, in section 5.8.7.1 (all in the Web addenda).
described
a shorter course of treatment was associated with a signicant re-
duction in major bleeds [OR 0.58 (95% CI 0.36, 0.92), P5.2.7.1
0.02], Upstream versus procedural initiation (see Web addenda)
while no statistically signicant differences in ischaemic 5.2.7.2
outcomes Combination with P2Y12 inhibitors (see Web addenda)
or stent thrombosis risks were observed, although a small to mod-
5.2.7.3 Adjunctive anticoagulant therapy (see Web addenda)
erate increase could not be excluded. Extended DAPT, 5.2.8comparedVorapaxar (see Web addenda)
with 12-month treatment, yielded a signicant reduction5.2.9 in MIRecommendations for platelet inhibition in
[OR 0.53 (95% CI 0.42, 0.66), P , 0.001] and stent thrombosis
non-ST-elevation acute coronary syndromes
[OR 0.33 (95% CI 0.21, 0.51), P , 0.001] while more major bleeds
occurred [OR 1.62 (95% CI 1.26, 2.09), P , 0.001]. In addition, all-
causedeathwassignicantlyincreasedintheextendedDAPTgroup
[OR 1.30 (95% CI 1.02, 1.66), P 0.03] while CV death did not dif-
fer among the groups.185 Recommendations for platelet inhibition in non-ST-
The Prevention of Cardiovascular Events in Patients withelevation
Prior acute coronary syndromes
Heart Attack Using Ticagrelor Compared to Placebo on a Back-
ground of Aspirin-Thrombolysis in Myocardial Infarction 54
(PEGASUS-TIMI 54) trial randomized 21162 patients who Recommendations
had had Classa Levelb Ref.c
an MI 13 years earlier to ticagrelor at a dose of 90 mg twice daily,
ticagrelor at a dose of 60 mg twice daily or placebo. 186 AtOral
a median
antiplatelet therapy
follow-up of 33 months, the study demonstrated a reduced rateisofrecommended for all
Aspirin
CV death, MI or stroke with ticagrelor [HR 0.85 (95% CI 0.75,patients without contraindications at
0.96), P 0.008 and HR 0.84 (95% CI 0.74, 0.95), P 0.004 for oral loading dosed of 150
an initial
90 mgand60 mgofticagrelorvs.placebo,respectively)andincreased300 mg (in aspirin-naiveI patients)
A 129 and
a
rates of major bleeding events (2.60% with 90 mg, 2.30% with 60 maintenance dose of 75100 132
mg/
mg daylong-termregardlessoftreatment
and 1.06% with placebo, P , 0.001).186 All-cause mortalitystrategy.
did not
differbetween thegroups.Ofimportance, mostpatientsbegantreat-
137,
ment with ticagrelor after an interruption in DAPT and all hadAprior P2Y12 inhibitor is recommended, in
148, I A
MI (context of secondary prevention in high-risk patients), while addition to aspirin, for 12 months
153
patients with a history of ischaemic stroke were excluded. In unlesstherearecontraindicationssuch
conclu-
sion, while a 1-year duration of DAPT in NSTE-ACS patients is as re-excessive risk of bleeds.
Ticagrelor (180mg loading dose,
commended, based on individual patient ischaemic and bleeding 90 mg twice daily) is recommended,
risk proles, DAPT duration may be shortened (i.e. 36 months) in the absence of contraindications, e
or extended (i.e. up to 30 months) in selected patients if required.for all patients at moderate-to-high
riskofischaemic events(e.g.elevated
5.2.7 Glycoprotein IIb/IIIa inhibitors cardiac troponins), regardless of I B 153
Intravenous GPIIb/IIIa inhibitors block platelet aggregation by initial treatment strategy and
inhibiting brinogen binding to a conformationally activated including those pretreated with
clopidogrel (which should be
form of the GPIIb/IIIa receptor on two adjacent platelets.128 A discontinued when ticagrelor is
meta-analysis of six RCTs involving 29 570 NSTE-ACS patients,started).
mainly medically managed, showed a 9% RRR in death or non-fatal
MI with GPIIb/IIIa inhibitors (10.7% vs. 11.5%, P 0.02) when Prasugrel (60 mg loading dose,
added to heparin.196 The greatest benet was observed in patients 10 mg daily dose)I is B 148,
undergoing PCI while on these agents [10.5% vs. 13.6%; OR 0.74 recommended 164
(95% CI 0.57, 0.96), P 0.02]. The use of GPIIb/IIIa inhibitors in patients who are proceeding
was associated with an increase in major bleeding complications to
Clopidogrel (300600 mg loading
PCI if no contraindication. e
without a signicant increase in intracranial haemorrhage. Many dose, 75 mg daily dose) is
of these trials predated the routine use of P2Y12 inhibitors. While
recommended for Ipatients
B 137 who
the relative efcacy of prasugrel and ticagrelor in the trials cannot receive ticagrelor or
prasugrel or who require oral
anticoagulation.
5.3.1.3 Fondaparinux
TheparenteralselectivefactorXainhibitorfondaparinuxisasynthet-
ic pentasaccharide that binds reversibly and non-covalently to
ESC Guidelines 289
IIb i.v.
Additional ACT-guided B boluses
231 of
UFH during PCI may be considered
following initial UFH
Discontinuation treatment.
of anticoagulation
should be considered after PCI, unless
IIa C
otherwise indicated.
290 ESC Guidelines
Crossover between UFH and LMWH Table 12 Suggested strategies to reduce bleeding risk
is not recommended. III B 216 related to PCI
Low to High
Bleedin
intermediate (e.g. HAS-
3)
g risk
(e.g. HAS-BLED BLED
= 02)
Triple or
dual
O A C
0 therapya
Triple
O A C
therapy
Dual
therap
Dual
4 yb
therap
weeks Dual
yb
therap
yb
6
month O C or A O C or A O C or A
s12 months
O Monother
Lifelong
apyc
O A C
Aspirin 75100 mg daily Clopidogrel
Oral anticoagulation 75 mg daily
(VKA or NOACs)
ACS = acute coronary syndrome; CABG = coronary artery bypass graft; CHA 2DS2-VASc = Cardiac failure, Hypertension, Age e75 [2 points],
Diabetes, Stroke [2 points]
Vascular disease, Age 6574, Sex category; DAPT = dual antiplatelet therapy; NOACs = non-vitamin K antagonist oral anticoagulants; NSTE-ACS =
non-ST-elevation acute
coronary syndrome; PCI = percutaneous coronary intervention; VKAs = vitamin K antagonists. Adapted from Lip et al. 234
aDual therapy with oral anticoagulation and clopidogrel may be considered in selected patients (low ischaemic risk).
bAspirin as an alternative to clopidogrel may be considered in patients on dual therapy (i.e., oral anticoagulation plus single antiplatelet); triple
Symptoms
Onset
High High
Same-day transfer
Intermedi Intermed
ate iate
Transfer
Low Low
Transfer
optional
Figure 6 Selection of non-ST-elevation acute coronary syndrome (NSTE-ACS) treatment strategy and timing according to initial risk
stratication.
5.6.3.4 Selective invasive strategy NSTEMI.333 In 36% of the patients, clopidogrel was prescribed within
Patients with no recurrence of symptoms and none7of days
the ofcriteria
discharge. In 8562 propensity scorematched patients, pa-
listed in Table 13 are to be considered at low risk of tients
ischaemic
who were prescribed clopidogrel had lower rates of all-cause
events. In these patients, a non-invasive stress test mortality
(preferably [8.3% vs. 13.0%; adjusted HR 0.63 (95% CI 0.54, 0.72), P,
withimaging)forinducibleischaemiaisrecommendedbeforedecid-
0.01] and the composite of death or MI [13.5% vs. 17.4%; HR 0.74
ing on an invasive strategy.331 (95% CI 0.66, 0.84), P , 0.01], but not MI alone [6.7% vs. 7.2%; HR
0.93 (95% CI 0.78, 1.11), P 0.30], compared with non-users of
clopi-
In summary, available data indicate that an earlydogrel.as opposedThe association
to a between clopidogrel use and the composite
of
delayed invasive strategy is safe and associated with a lower risk of
refractory ischaemia and a shorter duration of hospital deathorMIwassignicantamongpatientspresentingwithNSTEMI[HR
stay. The se-
0.67(95%CI0.59,0.76)]comparedwiththosepresentingwithunstable
lection of the optimal timing of invasive coronary angiography and
revascularization should be guided by individual risk angina [HR 1.25 (95% CI 0.94, 1.67), P for interaction ,0.01].
stratication.
It is recommended that patients at very high risk (i.e. The withTRILOGY
at least ACS trial randomized 7243 patients with NSTE-
ACS
onevery-high-riskcriterion)undergoanimmediateinvasivestrategy ,75yearsofageselectedformedicalmanagementtoclopido-
(,2 h). In patients at high risk (i.e. with at least onegrel or prasugrel
high-risk criter- for a median duration of 17 months. 334 Allocation
to prasugrel
ion), an early invasive strategy (,24 h) is recommended. In patients was not associated with a statistically signicant reduc-
tion in the
with at least one intermediate-risk criterion, the invasive strategy primary endpoint of death from CV causes, MI or stroke
[13.9%
may be delayed but a maximum 72 h window from admission to in the prasugrel group and 16.0% in the clopidogrel group;
HR
coronary angiography is recommended. In low-risk patients, a 0.91 (95% CI 0.79, 1.05), P 0.21]. While non-CABG TIMI ma-
jor bleeding
non-invasive stress test (preferably with imaging) for inducible is- rates did not differ among the groups, TIMI major and
minor
chaemia is recommended before deciding on an invasive strategy. bleeding events were more frequent in the prasugrel group
[1.9%vs.1.3%;HR1.54(95%CI1.06,2.23),P 0.02].InthePLATO
study, 5216 patients (28% of the total PLATO population) admitted
5.6.4 Conservative treatment to hospital for ACS were specied as planned for non-invasive man-
5.6.4.1 In patients with coronary artery disease agement, although by the end of follow-up, 3143 (60.3%) patients
5.6.4.1.1 Non-obstructive CAD. A pooled data analysis had beenfrom eight
managed non-invasively. In the population intended for
NSTE-ACS RCTs showed that 9.6% of the patients had non-
non-invasive management, the incidence of the primary endpoint,
obstructive CAD. Compared with patients with obstructivea composite CAD,of CV death, MI and stroke, was lower with ticagrelor
those individuals were younger and more often female, while fewer
than with clopidogrel [12.0% vs. 14.3%; HR 0.85 (95% CI 0.73, 1.00,
had diabetes mellitus, previous MI or prior PCI. Thirty-day death
P 0.04]. Overall or mortality was also lower [6.1% vs. 8.2%; HR 0.75
MI was less frequent among patients with non-obstructive(95% CI CAD 0.61, 0.93), P 0.01]. The incidence of non-CABG TIMI
(2.2%) vs. obstructive CAD (13.3%) [adjusted OR 0.15 major (95%bleedsCI was numerically higher in the ticagrelor-treated pa-
0.11, 0.20)]. Thirty-day death or MI and 6-month mortality were
tients [2.8% vs. 2.2%; HR 1.33 (95% CI 0.91, 1.94), P 0.142]. 335
also lower among patients with non-obstructive CAD [adjusted
OR 0.19 (95% CI 0.14, 0.25) and adjusted OR 0.37 (95% CI 0.28,
0.49), respectively].332 While invasive evaluation and, 5.6.4.1.2 CAD not amenable to revascularization. Data regarding pa-
if appropriate
tients
and feasible, revascularization are indicated in patients at high with ACS is- who are not amenable to revascularization due
chaemic risk, in a proportion of them this strategy is not offered be-CAD are sparse. The available observational stud-
to severe/diffuse
cause of the perception that patients might not benet ies included
in terms mainly
of patients with stable CAD and refractory an-
gina.
event reductiondue to the estimated increased risk related to 336,337 Although the prognosis differs according to patient
5.8.3 Chronic kidney disease (see Web addenda) 5.8.4 Left ventricular dysfunction and heart failure
5.8.3.1 Dose adjustment of antithrombotic agents (see Web
(see Web addenda)
addenda) 5.8.4.1 Recommendations for the management of
5.8.3.2 Recommendations for the management of patientspatients
with with
chronic acute heart failure in the setting of non-ST-elevation
kidney disease and non-ST-elevation acute coronary syndromes
acute
coronary syndromes
Recommendations for the management of patients Recommendations for the management of patients
with chronic kidney disease and non-ST-elevation with acute heart failure in the setting of non-ST-
acute coronary syndromes elevation acute coronary syndromes
5.8.4.2 Recommendations for the management of patients 5.8.5 Atrial brillation (see Web addenda)
with 5.8.5.1 Recommendations for the management of atrial
heart failure following non-ST-elevation acute coronary brillation in
syndromes patients with non-ST-elevation acute coronary syndromes
Recommendations for the management of patients Recommendations for the management of atrial
with heart failure following non-ST-elevation acute brillation in patients with non-ST-elevation acute
coronary syndromes coronary syndromes
Recommendations Class
469,a Levelb Ref.c Recommendations Classa Levelb Ref.c
478 I A I A 497
An ACE inhibitor(orARB,if an481 ACE In the absence of contraindications, it
inhibitor is not tolerated) is is recommended to administer
recommended in patients with LVEF anticoagulant drugs to all patients at
d40% after stabilization, to reduce Investigationstodetectischaemiashould
presentation.
A beta-blocker is recommended be considered in patients
IIa C with atrial
the risk of death, recurrent 469,
MI and
in patients with an LVEF d40% brillationandelevatedcardiactroponin
hospitalization for heart failure.
482the I A
after stabilization, to reduce levels.
risk of death, recurrent MI486
and
hospitalization for heart failure. Patients with rapid ventricular rate
Mineralocorticoid receptor Electrical cardioversion is
antagonists are recommended to recommended in haemodynamically
I C
reduce the risk of heart failure unstable patients.
hospitalization and death in all Electrical or pharmacological
patients with persistent symptoms cardioversion with amiodarone is
(NYHA class IIIV) and LVEF d35% I A 487, recommended in patients when a
despite treatment with an ACE 488 decision is made to restore sinus
inhibitor (or an ARB, if an ACE rhythm non-urgently (rhythm control
inhibitor is not tolerated) and a strategy). This strategy should only be
beta-blocker. employed in patients with the rst
I C
episode of atrial brillation of ,48 h
Mineralocorticoid receptor duration (or in patients with no
antagonists, preferably evidence of left atrial appendage
eplerenone, I B 469, thrombus on TOE) or if the patient
arerecommendedtoreducetheris525 was anticoagulated in the therapeutic
k range for at least 3 weeks.
of cardiovascular hospitalization
and Intravenous beta-blockers are
Device
death intherapy (CRT-D
patients or ICD,
with LVEF recommended to slow the rapid
depending
d40%. on QRS duration) is
ventricular response
I toCatrial
recommended in symptomatic
brillation in haemodynamically
patients with severe LV dysfunction
I A 489, stable
(LVEF d35%) despite optimal
490 patients.
medical therapy .40 days after the
acute event and without options of
revascularization. Patients should be Intravenous administration of cardiac
expected to survive .1 year with glycosides may beIIb C
considered for
good functional status. ventricular rate control if the
In patients with CAD and LVEF response to beta-blockers is not
d35%, testing for residual sufcient.
ischaemia Intravenous administration of
and subsequent non-dihydropyridine calcium
revascularization antagonists (verapamil, diltiazem)IIbmayC
should be considered prior to IIa B 491, be considered to slow a rapid
primary prophylactic ICD/CRT-D 492
ventricular response to atrial brillation
implantation. After in patients not on beta-blockers and
revascularization, with no signs of heart failure.
assessmentofreverseLVremodell Administration of class I
ing antiarrhythmic agents
III (e.g.
B 498
upto6monthsshouldbeconsidere encainide,
d angiotensin-converting enzyme; ARB angiotensin receptor
ACE ecainide) is not recommended.
Vernakalant is not recommended. III C 493
prior to primary prophylactic
blocker;
CAD coronary artery disease; CRT-D cardiac resynchronization
ICD/
therapy
CRT-D implantation.
debrillator; ICD implantable cardioverter debrillator; LV left TOE transoesophageal echocardiography.
ventricular; LVEF left ventricular ejection fraction; MI myocardial aClass of recommendation.
infarction; NYHA New York Heart Association. bLevel of evidence.
aClass of recommendation.
cReferences supporting level of evidence.
bLevel of evidence.
cReferences supporting level of evidence.
304 ESC Guidelines
5.8.6 Anaemia (see Web addenda) should be increased in those receiving a low- or moderate-intensity
5.8.7 Thrombocytopenia statin treatment at presentation, unless they have a history of in-
5.8.7.1 tolerance to high-intensity statin therapy or other characteristics
that may inuence safety.522,527,528 In this regard, the IMProved Re-
ThrombocytopeniarelatedtoGPIIb/IIIainhibitors(Webaddenda)
duction of Outcomes: Vytorin Efcacy International Trial
5.8.7.2 Heparin-induced thrombocytopenia (Web addenda)
5.8.7.3 Recommendations for the management of (IMPROVE-IT) randomized a total of 18 144 patients with recent
thrombocytopenia in ACS (NSTEMI 47%, STEMI 29% and unstable angina 24%) and
non-ST-elevation acute coronary syndromes LDL cholesterol ,125 mg/dL (,2.5 mmol/L) to either ezetimibe
10 mg/simvastatin 40 mg or simvastatin 40 mg (simvastatin was
up-titrated to 80 mg if LDL cholesterol was .79 mg/dL or
2.04 mmol/L). Over a period of 7 years, the composite primary end-
Recommendations for the management of
pointofCVdeath,MI,hospitaladmissionforunstableangina,coronary
thrombocytopenia in non-ST-elevation acute
revascularization or stroke was signicantly lower in the combined
coronary syndromes
treatment arm compared with the statin-only arm [32.7% vs.
34.7%;
HR 0.94 (95% CI0.89, 0.99), P 0.016].529 IMPROVE-ITwas the rst
Recommendations Classa Levelb Ref.c study powered for clinical outcomes to show a modest benet with a
non-statinagentaddedtoastatin.Asalimitation,notallpatientsinthe
Immediate interruption of GPIIb/IIIa control arm were on a high-intensity statin regimen. Based on the
inhibitor and/or heparin (UFH, re-
I C
LMWH, other heparin products) is sults of the trial, further LDL cholesterol lowering with a non-statin
recommended in case of agent should be considered in patients with LDL cholesterol
thrombocytopenia ,100 000/mL (or
.50% relative drop from baseline
e70 mg/dL (e1.8 mmol/L) after NSTE-ACS despite a maximally
platelet count) occurring during tolerated dose of statin. At the time of nalizing the guidelines, this
In patients treated with GP IIb/IIIa recommendation applies only to ezetimibe.
treatment.
inhibitors, platelet transfusion is
recommended in case of major
I C 5.9.1.2 Antithrombotic therapy
active
bleeding events or in the presence Duration of antiplatelet treatment and anticoagulation during the
of chronic phase are discussed in sections 5.2.6 and 5.3.2,
severe (,10000/mL) asymptomatic respectively.
thrombocytopenia.
Treatment with a non-heparin
I C
anticoagulant is recommended in case 5.9.1.3 ACE inhibition
of documented or suspected HIT. ACE inhibitors are recommended in patients with systolic LV dys-
Use of anticoagulants with low or no
risk of HIT or brief administration of functionorheartfailure,hypertensionordiabetes(agentsanddoses
UFH or LMWH, when these are of proven efcacy should be employed). ARBs are indicated in pa-
I C
chosen, are recommended to prevent tients who are intolerant of ACE inhibitors. 478480,530,531
the occurrence of HIT.
5.9.1.4
GP glycoprotein; HIT heparin-induced thrombocytopenia; LMWH Beta-blockers
low
molecular weight heparin; UFH unfractionated heparin. Beta-blockersarerecommended,intheabsenceofcontraindications,
aClass of recommendation.
in patients with reduced systolic LV function (LVEF d40%). Agents
bLevel of evidence.
cReferences supporting level of evidence.
and doses of proven efcacy should be administered. 482486 Beta-
blocker therapy has not been investigated in contemporary RCTs
in patients after NSTE-ACS and no reduced LV function or heart fail-
ure. In a large-scale observational propensity-matched study in pa-
5.8.8 Patients requiring chronic analgesic or tients with known prior MI, beta-blocker use was not associated
anti-inammatory treatment (see Web addenda) with a lower risk of CV events or mortality. 532
5.8.9 Non-cardiac surgery (see Web addenda)
5.9Long-term management
5.9.1 Medical therapy for secondary prevention 5.9.1.5 Mineralocorticoid receptor antagonist therapy
SecondarypreventionofCVevents,includingoptimalmedicaltherapy,
AldosteroneantagonisttherapyisrecommendedinpatientswithLV
otherstrategiesforriskfactormodicationandlifestylechangessuchas
dysfunction (LVEF d40%) and heart failure or diabetes after
diet, exercise and smoking cessation, is of paramount importance
NSTE-ACS.Eplerenonetherapyhasbeenshownto reducemorbid-
be- ity and mortality in these patients after ACS.487,488,525
cause after an ACS episode, patients remain at high risk for
recurrent
ischaemic events.521 Secondary prevention has been shown to
have a 5.9.1.6 Antihypertensive therapy
Antihypertensive therapy (blood pressure goal ,140/90 mmHg)
majorimpactonlong-termoutcomeinthesepatients. 478,479,482,521526
is recommended according to the European Society of
Hypertension/ESC guidelines on the management of arterial
hypertension.533
5.9.1.1 Lipid-lowering treatment
It is recommended to initiate high-intensity statin therapy [i.e.
statin
5.9.1.7 Glucose-lowering
regimens that reduce low-density lipoprotein (LDL) cholesterol by therapy in diabetic patients
Thistopicisbeyondthescopeofthepresentdocumentandwasdis-
50%] as earlyas possible afteradmission in all NSTE-ACS patients
(in the absence of contraindications). The intensity ofcussed
statin in recent guidelines.433 As a general rule, the more
therapy advanced
ESC Guidelines 305
the CV disease, the older the patient, the longer the diabetes dur-
Participationinawell-
ationandthemorecomorbiditiesthatarepresent,thelessstringent structuredcardiac
535,
the glucose control should be. 541 IIa A
rehabilitation programme to
Core components and goals of cardiac rehabilitation, including 546
modify
physical activity counselling, diet/nutrition counselling, smoking
lifestyle habits and increase
ces- In patients with LDL cholesterol
adherence
e70
sation, weight control and goals for lipid and blood pressure man- mg/dL (e1.8
to treatment mmol/L)
should be despite a
maximally IIa B statin
considered.tolerated 529 dose, further
agement should be stated in the discharge letter. 534
reduction in LDL cholesterol with a
non-statin agente should be considered.
5.9.2 Lifestyle changes and cardiac rehabilitation
Enrolment in a well-structured cardiac rehabilitation/secondary pre-
vention programme after NSTE-ACS should be considered,A as systolic
it canblood pressure goal
enhance patient compliance with the medical regimen and of promote
,140mmHgshouldbeconsidered. IIa B 547
lifestyle changes, including regular physical exercise and smoking 549
ces-
sation,andallowsfordietarycounselling.521,535Aerobicexercisetrain-
ing within a cardiac rehabilitation programme should be ACEoffered to
angiotensin-converting enzyme; ARB angiotensin receptor blocker;
patients after NSTE-ACS, with the need for an evaluationLDL low-density lipoprotein; LVEF left ventricular ejection fraction;
of both
NSTE-ACS non-ST-elevation acute coronary syndromes.
ex- aClass of recommendation.
ercisecapacityandexercise-associatedrisk.Iffeasible,regularexercise
bLevel of evidence.
The CME text 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation is accredited
by the European
Board for Accreditation in Cardiology (EBAC). EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical
Education (EACCME),
which is an institution of the European Union of Medical Specialists (UEMS). In compliance with EBAC/EACCME Guidelines, all authors participating in this
programme have disclosed
any potential conicts of interest that might cause a bias in the article. The Organizing Committee is responsible for ensuring that all potential conicts of interest
relevant to the
programme are declared to the participants prior to the CME activities.
CME questions for this article are available at: European Heart Journal http://www.oxforde-learning.com/eurheartj and European Society of Cardiology
http://www.escardio.org/
guidelines. Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W,
13.References Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC,
Armstrong PW, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G,
1. Steg PG, James SK, Atar D, Badano LP, Blomstrom-LundqvistLuepkerC, BorgerRV,MA, Di
Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D,
Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, GershlickLopez-Sendon
AH, JL, Robertson RM, Weaver D, Tendera M, Bove AA,
Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Parkhomenko
Lenzen MJ, AN, Vasilieva EJ, Mendis S. Third universal denition of myocardial
Mahaffey KW, Valgimigli M, van t Hof A, Widimsky P, Zahger D. ESC guidelines
infarction. Eur Heart J 2012;33:25512567.
for the management of acute myocardial infarction in patients presenting
3. Roe with
MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM,
ST-segment elevation. Eur Heart J 2012;33:25692619. Simoons ML, Akkerhuis M, Ohman EM, Kitt MM, Vahanian A, Ruzyllo W,
2. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, WhiteKarschHD,K, Katus HA, Topol EJ. Clinical and therapeutic prole of patients present-
Califf RM,
Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, ing Johanson
with acuteP,coronary syndromes who do not have signicant coronary artery
Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA,
310 ESC Guidelines
102. DresslerR,DryerMM,ColettiC,MahoneyD,DooreyAJ.Alteringoveruseofcar-
therapy: results from the American College of Cardiologys NCDRw. Am Heart J
diac telemetry in non-intensive care unit settings by hardwiring 2011;161:864870.
the use of Ameri-
can Heart Association guidelines. JAMA Intern Med 2014;174:18521854.
121. Theroux P, Taeymans Y, Morissette D, Bosch X, Pelletier GB, Waters DD. A ran-
103. FoxKA,AndersonFAJr, Goodman SG,StegPG,PieperK,QuillA,GoreJM.Time
domized study comparing propranolol and diltiazem in the treatment of unstable
course of events in acute coronary syndromes: implications for angina.
clinical J Ampractice
Coll Cardiol 1985;5:717722.
from the grace registry. Nat Clin Pract Cardiovasc Med 2008;5:580589.
122. Parodi O, Simonetti I, Michelassi C, Carpeggiani C, Biagini A, LAbbate A,
104. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane Maseri AJ,A.Parise
Comparison
H, of verapamil and propranolol therapy for angina pectoris
Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumiat rest: a G, randomized, multiple-crossover, controlled trial in the coronary care
Lansky AJ, Stone GW. A risk score to predict bleeding in patients unit.withAmacuteJ Cardiolcor-1986;57:899906.
onary syndromes. J Am Coll Cardiol 2010;55:25562566. 123. LubsenJ,TijssenJG.Efcacyofnifedipineandmetoprololintheearlytreatmentof
105. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, BadimonunstableL, Bassand angina
JP, De in the coronary care unit: ndings from the Holland Interuniver-
Caterina R, Eikelboom JA, Gulba D, Hamon M, Helft G, Fox KA,sity Kristensen
Nifedipine/Metoprolol
SD, Trial (HINT). Am J Cardiol 1987;60:18A25A.
Rao SV, Verheugt FW, WidimskyP, Zeymer U, Collet JP. Bleeding 124. Hansen
in acuteJF. coron-
Treatment with verapamil afteran acute myocardial infarction. Review
ary syndromes and percutaneous coronary interventions: position oftheDanishStudiesonVerapamilinMyocardialInfarction(DAVITIandII).Drugs
paper by the
working group on thrombosis of the European Society of Cardiology.1991;42(Suppl Eur Heart 2):4353.
J 2011;32:18541864. 125. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A,
106. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, VarshavskyS,
Wang TY, WolffAA,SkeneA,McCabe CH,BraunwaldE. Effectsofranolazine
GiblerWB,OhmanEM,RoeMT,PollackCVJr,PetersonED,AlexanderKP.Base- on recurrent cardiovascular events in patients with non-ST-elevation acute cor-
lineriskofmajorbleedinginnon-ST-segment-elevationmyocardialinfarction:the
onary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007;297:
CRUSADE (Can Rapid risk stratication of Unstable angina patients 17751783.Suppress
ADverse outcomes with Early implementation of the ACC/AHA 126.guidelines)
Miller CD, Roe MT, Mulgund J, Hoekstra JW, Santos R, Pollack CV Jr, Ohman EM,
bleeding score. Circulation 2009;119:18731882. Gibler WB, Peterson ED. Impact of acute beta-blocker therapy for patients with
107. Abu-Assi E, Raposeiras-Roubin S, Lear P, Cabanas-Grandio non-ST-segment
P, Girondo M, elevation myocardial infarction. Am J Med 2007;120:685692.
Rodriguez-Cordero M, Pereira-Lopez E, Romani SG, Gonzalez-Cambeiro
127. Yasue H,C,Takizawa A, Nagao M, Nishida S, Horie M, Kubota J, Omote S,
Alvarez-Alvarez B, Garcia-Acuna JM, Gonzalez-Juanatey JR. Comparing
Takaoka K, the
Okumura
pre- K. Long-term prognosis for patients with variant angina
dictive validity of three contemporary bleeding risk scores in and acute inuential
coronary factors.
syn- Circulation 1988;78:19.
drome. Eur Heart J Acute Cardiovasc Care 2012;1:222231. 128. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, De
108. Weber M, Bazzino O, Navarro Estrada JL, de Miguel R, Salzberg Caterina S, Fuselli
R, Gulba
JJ, D, Huber K, Husted S, Kristensen SD, Morais J, Neumann FJ,
Liebetrau C, Woelken M, Moellmann H, Nef H, Hamm C. Improved Rasmussendiagnostic LH, Siegbahn A, Steg PG, Storey RF, Van de Werf F, Verheugt F. Anti-
and prognostic performance of a new high-sensitive troponinplateletT assay agents in patientsfor the treatment and prevention of atherothrombosis. Eur Heart J
with acute coronary syndrome. Am Heart J 2011;162:8188. 2011;32:29222932.
109. Akkerhuis KM, Klootwijk PA, Lindeboom W, Umans VA, Meij 129.S,Risk
Kint of PP,myocardial infarction and death during treatment with low dose aspirin
Simoons ML. Recurrentischaemia during continuous multileadand ST-segment
intravenous mon- heparin in men with unstable coronary artery disease. The
itoring identies patients with acute coronary syndromes at high RISC risk
group.
of adverse
Lancet 1990;336:827830.
cardiac events; meta-analysis of three studies involving 995 130.
patients.
Lewis HD EurJr,
Heart
DavisJ JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE
2001;22:19972006. 3rd, SchnaperHW, LeWinterMM,LinaresE,PougetJM,SabharwalSC,CheslerE,
110. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger DeMots
J, Meinertz
H. Protective
T. effects of aspirin against acute myocardial infarction and
Emergencyroomtriageofpatientswithacutechestpainbymeansofrapidtesting
death in men with unstable angina. Results of a Veterans Administration cooperative
for cardiac troponin T or troponin I. N Engl J Med 1997;337:16481653.
study. N Engl J Med 1983;309:396403.
111. AntmanEM,TanasijevicMJ,ThompsonB,SchactmanM,McCabeCH,CannonCP,
131. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M,
Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Stasiak Cardiac-specicJ, deGuise P, PelletierGB, Rinzler D, WatersDD. Aspirin, heparin, orboth
troponin I levels to predict the risk of mortality in patients with
to acute
treat acute
coronary unstable angina. N Engl J Med 1988;319:11051111.
syndromes. N Engl J Med 1996;335:13421349. 132. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G,
112. Scirica BM, Morrow DA, Budaj A, Dalby AJ, Mohanavelu S, Qin KostukJ, Aroesty
WJ, Melendez
J, LJ, Myers MG, Sackett DL, Sealey BJ, Tanser PH. Aspirin,
Hedgepeth CM, Stone PH, Braunwald E. Ischemia detected onsulnpyrazone,
continuous elec- or both in unstable angina. Results of a Canadian multicenter trial.
trocardiographyafteracute coronarysyndrome:observations fromthe N Engl JMERLIN-Med 1985;313:13691375.
TIMI 36 (metabolic efciency with ranolazine for less ischemia 133.in Antithrombotic Trialists Collaboration. Collaborative meta-analysis of rando-
non-ST-elevation acute coronary syndrome-thrombolysis in myocardial
mised trials infarc-
of antiplatelet therapy for prevention of death, myocardial infarction,
tion 36) trial. J Am Coll Cardiol 2009;53:14111421. and stroke in high risk patients. BMJ 2002;324:7186.
113. Nyman I, Wallentin L, Areskog M, Areskog NH, Swahn E. 134. Risk stratication
Mehta SR,BassandJP,Chrolavicius
by S,DiazR,EikelboomJW,FoxKA,GrangerCB,
early exercise testing after an episode of unstable coronary artery
Jolly S,disease.
Joyner CD, TheRupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S. Dose
RISC study group. Int J Cardiol 1993;39:131142. comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J
114. Amsterdam EA, Kirk JD, Diercks DB, Lewis WR, Turnipseed SD. MedImmediate
2010;363:930942. ex-
ercise testing to evaluate low-risk patients presenting to the 135.
emergency
Savi P, Labouret
depart- C, Delesque N, Guette F, Lupker J, Herbert JM. P2Y 12, a new
ment with chest pain. J Am Coll Cardiol 2002;40:251256. platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun
115. Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray2001;283:379383.
JE, Cameron P,
Barger B, Ellims AH, Taylor AJ, Meredith IT, Kaye DM. Air versus
136. oxygen
Savi P, Herbert
in JM. Clopidogrel and ticlopidine: P2Y12 adenosine
ST-segment-elevation myocardial infarction. Circulation 2015;131:21432150.
diphosphate-receptorantagonists for the prevention of atherothrombosis. Semin
116. Borzak S, Cannon CP, Kraft PL, Douthat L, Becker RC, Palmeri ThrombST, HenryHemost T, 2005;31:174183.
HochmanJS,FuchsJ,Antman EM,McCabe C,BraunwaldE. Effectsofprioraspirin
137. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopido-
and anti-ischemic therapy on outcome of patients with unstable grelangina.
in addition TIMIto 7 aspirin in patients with acute coronary syndromes without
Investigators. Thrombin inhibition in myocardial ischemia. AmST-segment
J Cardiol 1998;81:elevation. N Engl J Med 2001;345:494502.
678681. 138. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K,
117. Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5
Rupprecht inhibitors
H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment
used for the treatment of erectile dysfunction or pulmonary hypertension.
withclopidogrelandaspirinfollowedbylong-termtherapyinpatientsundergoing
Circulation 2010;122:8895. percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:
118. Yusuf S, Wittes J, Friedman L. Overview of results of randomized
527533. clinical trials in
heart disease. I. Treatments following myocardial infarction. 139.
JAMA Parodi
1988;260:
G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P,
20882093. Gensini GF, Abbate R, Antoniucci D. High residual platelet reactivity after clopi-
119. Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, dogrel
Bangalore
loading S,and long-term cardiovascular events among patients with acute
Mukherjee D. Early intravenous beta-blockers in patients withcoronaryacute coronarysyndromes undergoing PCI. JAMA 2011;306:12151223.
syndromea meta-analysis of randomized trials. Int J Cardiol140. 2013;168:915921.
Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I,
120. Kontos MC, Diercks DB, Ho PM, Wang TY, Chen AY, Roe MT.NovikovI,PresH,SavionN,VaronD,HodH.Clopidogrelresistanceisassociated
Treatment and
outcomes in patients with myocardial infarction treated with with acuteincreased
beta-blocker risk of recurrent atherothrombotic events in patients with acute
myocardial infarction. Circulation 2004;109:31713175.
314 ESC Guidelines
141. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM,Skerjanec Ferenc M,S,Gick BhattM,DL. Platelet inhibition with cangrelor in patients undergoing
Caputo A, Buttner HJ, Neumann FJ. Impact of the degree of peri-interventional
PCI. N Engl J Med 2009;361:23182329.
plateletinhibitionafterloadingwithclopidogrelonearlyclinicaloutcomeofelect-
159. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G,
ive coronary stent placement. J Am Coll Cardiol 2006;48:17421750. Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr,
142. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A,Manoukian
Kastrati A, SV, von Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ,
Beckerath N. Platelet reactivity after clopidogrel treatment assessed
Arneja J,with Skerjanec S, Harrington RA. Intravenous platelet blockade with cangre-
point-of-care analysis and early drug-eluting stent thrombosis. lorJ Am
duringCollPCI.
Cardiol
N Engl J Med 2009;361:23302341.
2009;53:849856. 160. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ,
143. Aradi D, Storey RF, Komocsi A, Trenk D, Gulba D, Kiss RG, Husted Leonardi S, S,
Bonello
GallupL,D, Bramucci E, Radke PW, Widimsky P, Tousek F, Tauth J,
Sibbing D, Collet JP, Huber K. Expert position paper on the role Spriggs
of platelet
D, McLaurin
func- BT, Angiolillo DJ, Genereux P, Liu T, Prats J, Todd M,
tion testinginpatients undergoing percutaneous coronaryintervention.SkerjanecS,WhiteHD,Harrington
Eur Heart RA.Effectofplateletinhibitionwithcangrelor
J 2014;35:209215. during PCI on ischemic events. N Engl J Med 2013;368:13031313.
144. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet161. E, Meneveau
StegPG,BhattDL,HammCW,StoneGW,GibsonCM,MahaffeyKW,LeonardiS,
N,
Steg PG, Ferrieres J, Danchin N, Becquemont L. Genetic determinants Liu T, Skerjanec
of re- S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L,
sponse to clopidogrel and cardiovascular events. N Engl J MedFrenchWJ,WhiteHD,
2009;360: Harrington RA.Effect of cangreloronperiproceduralout-
363375. comes in percutaneous coronary interventions: a pooled analysis of patient-level
145. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot
data. L, Brugier
Lancet 2013;382:19811992.
D,
Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot 162. Hamm
G. Cytochrome
CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D,
P450 2C19 polymorphism in young patients treated with clopidogrel Gielen S, after
Hubermyo-K,Ohman M,PetrieMC, Sonntag F, Uva MS,StoreyRF, Wijns W,
cardial infarction: a cohort study. Lancet 2009;373:309317. Zahger D. ESC guidelines for the management of acute coronary syndromes in
146. Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping: patients
one piece
presenting
of the without persistent ST-segment elevation: the Task Force
puzzle to personalize antiplatelet therapy. J Am Coll Cardiol 2010;56:112116.
for the management of acute coronary syndromes (ACS) in patients presenting
147. CaylaG,HulotJS,OConnorSA,PathakA,ScottSA,GruelY,SilvainJ,VignalouJB,
without persistent ST-segment elevation of the European Society of Cardiology
Huerre Y, de la Briolle A, Allanic F, Beygui F, Barthelemy O, Montalescot
(ESC). Eur Heart G, J 2011;32:29993054.
ColletJP.Clinical,angiographic,andgeneticfactorsassociatedwithearlycoronary
163. Bellemain-Appaix A,Brieger D, BeyguiF, Silvain J, PenaA, CaylaG, Barthelemy O,
stent thrombosis. JAMA 2011;306:17651774. Collet JP, Montalescot G. New P2Y12 inhibitors versus clopidogrel in percutan-
148. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo eouscoronaryintervention:ameta-analysis.JAmCollCardiol2010;56:15421551.
W, Gottlieb S,
Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer 164.
J, Weerakkody
MontalescotG, G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten
Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients Berg with
JM, acute
Miller cor-
DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J,
onary syndromes. N Engl J Med 2007;357:20012015. Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E,
149. De Servi S, Goedicke J, Schirmer A, Widimsky P. Clinical outcomesWidimsky forP.Pretreatmentwithprasugrelinnon-ST-segmentelevationacutecor-
prasugrel
versus clopidogrel in patients with unstable angina or non-ST-elevation
onary syndromes.myocar- N Engl J Med 2013;369:9991010.
dial infarction: an analysis from the TRITON-TIMI 38 trial. Eur 165.
HeartCollet
J Acute
JP, Silvain
Cardi-J, Bellemain-Appaix A, Montalescot G. Pretreatment with P2Y 12
ovasc Care 2014;3:363372. inhibitors in non-ST-segment-elevation acute coronary syndrome: an outdated
150. Pena A, Collet JP, Hulot JS, Silvain J, Barthelemy O, Beygui F, and Funck-Brentano
harmful strategy. C, Circulation 2014;130:19041914.
Montalescot G. Can we override clopidogrel resistance? Circulation
166. Valgimigli
2009;119: M. Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation
28542857. acute coronary syndrome is clinically justied. Circulation 2014;130:18911903.
151. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, 167.
Herrman
Stone JP,GW, VanWitzenbichler
de B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC,
Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM. Intensive Henryoral TD, antipla-
Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H,
telet therapy for reduction of ischaemic events including stent Kirtane
thrombosis
AJ, Brodie
in pa-BR, Mehran R, Stuckey TD. Platelet reactivity and clinical out-
tients with acute coronary syndromes treated with percutaneous comes coronary
after coronary artery implantation of drug-eluting stents (ADAPT-DES): a
intervention and stenting in the TRITON-TIMI 38 trial: a subanalysisprospectiveof a rando-
multicentre registry study. Lancet 2013;382:614623.
mised trial. Lancet 2008;371:13531363. 168. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S,
152. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C,RobbinsTeng R, M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE,
Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy StinisD, CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ. Standard-
Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment vs high-dose of the clopidogrel
on- based on platelet function testing after percutaneous
set andoffset of theantiplatelet effects of ticagrelorversusclopidogrelinpatients
coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:
with stable coronaryartery disease: the Onset/Offset study.Circulation2009;120:
10971105.
25772585. 169. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U, Richardt G,
153. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson Jakubowski
H, Held C, Horrow JA, Neumann
J, FJ. A randomized trial of prasugrel versus clopidogrel
HustedS,JamesS,KatusH,MahaffeyKW,SciricaBM,SkeneA,StegPG,StoreyRF, in patients with high platelet reactivity on clopidogrel after elective percutaneous
Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel coronary
in patients
intervention
with with implantation of drug-eluting stents: results of the
acute coronary syndromes. N Engl J Med 2009;361:10451057.TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent
154. Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann PlacementA,on Maya
Clopidogrel
J, to Guide Alternative Therapy With Prasugrel) study.
Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin J AmL, James
Coll Cardiol
SK. Tica-2012;59:21592164.
grelorvs. clopidogrel inpatients with non-ST-elevation acutecoronarysyndrome
170. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P,
with or without revascularization: results from the PLATO trial.Carrie Eur Heart
D, Boueri
J 2014;Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monsegu J,
35:20832093. Sabouret P, OConnor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthelemy O,
155. Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey BeyguiF,SilvainJ,VicautE,MontalescotG.Bedsidemonitoringtoadjustantiplate-
KW, Meier B,
StoreyRF,WojdylaDM,LewisBS,MaurerG,Wallentin L,JamesSK.Stentthrom- let therapy for coronary stenting. N Engl J Med 2012;367:21002109.
bosis with ticagrelor versus clopidogrel in patients with acute 171. coronary
Mega JL,syn- Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM,
dromes: an analysis from the prospective, randomized PLATOBraunwald trial. Circulation
E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardio-
2013;128:10551065. vascular outcomes after treatment with clopidogrel and prasugrel in the
156. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools TRITON-TIMI
F, Steg 38 PG,trial: a pharmacogenetic analysis. Lancet 2010;376:13121319.
Khurmi NS, Emanuelsson H, Cooper A, Cairns R, Cannon CP, 172.
Wallentin
Trenk D, L. Hochholzer
Char- W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C,
acterization of dyspnoea in PLATO study patients treated withSchmiebusch
ticagrelor or P, clo-
Bestehorn HP, Buttner HJ, Neumann FJ. Cytochrome P450
pidogrel and its association with clinical outcomes. Eur Heart 2C19 J 2011;32:
681G.A polymorphism and high on-clopidogrel platelet reactivity asso-
29452953. ciated with adverse 1-year clinical outcome of elective percutaneous coronary
157. StoreyRF,OldroydKG,WilcoxRG.OpenmulticentrestudyoftheP2 intervention
Treceptor with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51:
antagonistAR-C69931MXassessingsafety,tolerabilityandactivityinpatientswith
19251934.
acute coronary syndromes. Thromb Haemost 2001;85:401407. 173. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR,
158. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM,Antman Gibson EM, CM,Macias WL, Braunwald E, Sabatine MS. Cytochrome P450 genetic
Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman polymorphisms
SG, and the response to prasugrel: relationship to pharmacokinetic,
Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leischpharmacodynamic,
F, Parikh KH, and clinical outcomes. Circulation 2009;119:25532560.
ESC Guidelines 315
174. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl
ofdualantiplatelettherapyafterzotarolimus-elutingstents:theOPTIMIZErando-
M, Dick A,
Marquis JF, OBrien E, Goncalves S, Druce I, Stewart A, GollobmizedMH,trial.
So DY JAMA
. 2013;310:25102522.
Point-of-care genetic testing for personalisation of antiplatelet
189. Gwontreatment
HC, Hahn (RAPIDJY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH,
GENE): a prospective, randomised, proof-of-concept trial. Lancet
Choi SH, 2012;379:
Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY,
17051711. Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK,
175. Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt
Jang Y,FW, KimHuber
HS. Six-month
K, versus 12-month dual antiplatelet therapy after im-
Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atarplantation
D, Pathak of A, drug-eluting stents: the efcacy of xience/promus versus cypher
KjeldsenK,StoreyRF.Expertpositionpaperontheuseofprotonpumpinhibitors
to reduce late loss after stenting (EXCELLENT) randomized, multicenter study.
in patients with cardiovascular disease and antithromboticCirculation
therapy. Eur 2012;125:505513.
Heart J
2013;34:17081713, 1713a1713b. 190. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F,
176. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, MagidColombo
DJ, Krumholz
F, Tebaldi HM,M, Fuca G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A,
Rumsfeld JS. Impact of medication therapy discontinuationCavazza
on mortality C, Frangione
after A, Borghesi M, Marchesini J, Parrinello G, Ferrari R. Short-
myocardial infarction. Arch Intern Med 2006;166:18421847. versus long-term duration of dual-antiplatelet therapy after coronary stenting: a
177. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler
randomized
B, Henrymulticenter
TD, trial. Circulation 2012;125:20152026.
Kini AS, Stuckey T, Cohen DJ, Berger PB, Iakovou I, Dangas 191.G,ColomboA,ChieffoA,FrasheriA,GarboR,Masotti-CentolM,SalvatellaN,Oteo
Waksman R,
Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Dominguez
Gibson CM, JF, Steffanon L, Tarantini G, Presbitero P, Menozzi A, Pucci E, Mauri J,
Chieffo A, Alu M, Moliterno DJ, Colombo A, Pocock S. Cessation
CesanaBM,GiustinoG,SardellaG.Second-generationdrug-elutingstentimplant-
of dual antipla-
telet treatment and cardiac events after percutaneous coronary
ation followed
intervention by 6- versus 12-month dual antiplatelet therapy: the SECURITY
(PARIS): 2 year results from a prospective observational study.
randomized
Lancet 2013;clinical trial. J Am Coll Cardiol 2014;64:20862097.
382:17141722. 192. Schulz-Schupke S, Byrne RA, ten Berg JM, Neumann FJ, Han Y, Adriaenssens T,
178. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, LockhartTolg PB, Moliterno
R, Seyfarth DJ,M, Maeng M, Zrenner B, Jacobshagen C, Mudra H, von
OGara P, Whitlow P. Prevention of premature discontinuation Hodenberg
of dual antiplate-
E, Wohrle J, Angiolillo DJ, von Merzljak B, Rifatov N, Kufner S,
let therapy in patients with coronary artery stents: a science
Morath
advisoryT, Feuchtenberger
from the A, Ibrahim T, Janssen PW, Valina C, Li Y, Desmet W,
American Heart Association, American College of Cardiology, Abdel-Wahab
Society forM, Car-
Tiroch K, Hengstenberg C, Bernlochner I, Fischer M,
diovascular Angiography and Interventions, American College Schunkert
of Surgeons,
H, Laugwitzand KL, Schomig A, Mehilli J, Kastrati A. ISAR-SAFE: a rando-
American Dental Association, with representation from themized,
American double-blind,
College placebo-controlled trial of 6 vs. 12 months of clopidogrel ther-
of Physicians. Circulation 2007;115:813818. apy after drug-eluting stenting. Eur Heart J 2015;36:12521263.
179. Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, 193.
Hert Gilard
SD, FordM, Barragan
I, P, Noryani AA, Noor HA, Majwal T, Hovasse T, Castellant P,
Gonzalez-Juanatey JR, Gorenek B, Heyndrickx GR, Hoeft A,Schneeberger
Huber K, Iung M, B, Maillard L, Bressolette E, Wojcik J, Delarche N, Blanchard D,
Kjeldsen KP, Longrois D, Luscher TF, Pierard L, Pocock S, Price
Jouve S, B,RofOrmezzano
M, O, Paganelli F, Levy G, Sainsous J, Carrie D, Furber A,
Sirnes PA, Sousa-Uva M, Voudris V, Funck-Brentano C. 2014 Berland
ESC/ESA J, Darremont
guidelines O, Le Breton H, Lyuycx-Bore A, Gommeaux A,
on non-cardiac surgery: cardiovascular assessment and management.
Cassat C, KermarrecEur Heart A,J Cazaux P, Druelles P, Dauphin R, Armengaud J,
2014;35:23832431. Dupouy P, Champagnac D, Ohlmann P, Endresen K, Benamer H, Kiss RG,
180. Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt
Ungi I, U, Boschat
NashefJ,SA. Morice MC. 6- versus 24-month dual antiplatelet therapy after
Guideline on antiplatelet and anticoagulation managementimplantation
in cardiac surgery.
of drug-eluting stents in patients nonresistant to aspirin: the rando-
Eur J Cardiothorac Surg 2008;34:7392. mized, multicenter ITALIC trial. J Am Coll Cardiol 2015;65:777786.
181. Savonitto S, DUrbano M, Caracciolo M, Barlocco F, Mariani
194. Lee
G, Nichelatti
CW, Ahn JM, M, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Han S, Lee SG,
Klugmann S, De Servi S. Urgent surgery in patients with a Seong
recently IW,implanted
Rha SW, cor- Jeong MH, Lim DS, Yoon JH, Hur SH, Choi YS, Yang JY,
onary drug-eluting stent: a phase II studyof bridging antiplatelet
Lee NH, therapy
Kim HS, with
Leetir-
BK, Kim KS, Lee SU, Chae JK, Cheong SS, Suh IW,
oban during temporary withdrawal of clopidogrel. Br J AnaesthPark 2010;104:
HS, Nah DY, Jeon DS, Seung KB, Lee K, Jang JS, Park SJ. Optimal duration
285291. of dual antiplatelet therapy after drug-eluting stent implantation: a randomized,
182. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra
controlled
M, Welsby trial.IJ,Circulation 2014;129:304312.
Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke 195. C,
Collet
Liu T,JP, Silvain J, Barthelemy O, Range G, Cayla G, Van Belle E, Cuisset T,
Montalescot G, Manoukian SV, Prats J, Topol EJ. Bridging antiplatelet
Elhadad S,therapySchiele F, Lhoest N, Ohlmann P, Carrie D, Rousseau H, Aubry P,
with cangrelor in patients undergoing cardiac surgery: a randomized
Monsegu J,controlled
Sabouret P, OConnor SA, Abtan J, Kerneis M, Saint-Etienne C,
trial. JAMA 2012;307:265274. BeyguiF,VicautE,MontalescotG.Dual-antiplatelettreatmentbeyond1yearafter
183. SteinhublSR,BergerPB,MannJT3rd,FryET,DeLagoA,WilmerC,TopolEJ.Early
drug-eluting stent implantation (ARCTIC-INTERRUPTION): a randomised trial.
and sustained dual oral antiplatelet therapy following percutaneous
Lancet 2014;384:15771585.
coronary
intervention: a randomized controlled trial. JAMA 2002;288:24112420.
196. Rof M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, Heeschen C,
184. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, CutlipHamm
DE, Steg CW, PG,
Robbins MA, Kleiman NS, Theroux P, White HD, Topol EJ. Platelet
Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR glycoprotein
Jr, IIb/IIIa inhibition in acute coronary syndromes. Gradient of benet re-
Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzarilated DE, Garratt
to the revascularization
KN, strategy. Eur Heart J 2002;23:14411448.
Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM. Twelve 197.
or 30
ODonoghue
months ofM, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A,
dual antiplatelet therapy after drug-eluting stents. N Engl JPenny
Med 2014;371:
WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD. The efcacy and
21552166. safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients
185. Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon
with acute
A, Brouwer
coronary M, syndromes undergoing percutaneous intervention: a
Costa F, Kowalewski M, Parati G, Lip GY, Kelm M, ValgimigliTRITON-TIMI
M. Optimal duration
38 (Trial to Assess Improvement in Therapeutic Outcomes by
of dual antiplatelet therapy after percutaneous coronary intervention
Optimizing Platelet
with drug Inhibition with PrasugrelThrombolysis in Myocardial Infarc-
eluting stents: meta-analysis of randomised controlled trials.
tionBMJ38)2015;350:
analysis. J Am Coll Cardiol 2009;54:678685.
h1618. 198. Stone GW,BertrandME,MosesJW, Ohman EM,LincoffAM, WareJH,PocockSJ,
186. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen McLaurin
EC, Magnani
BT, CoxG, DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH,
Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj Desaga
A, Theroux
M, Stuckey P, TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD.
Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, MurphyRoutine SA,upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhi-
Wiviott SD, Held P, Braunwald E, Sabatine MS. Long-term use bitors
of ticagrelor
in acute coronary
in pa- syndromes: the ACUITY timing trial. JAMA 2007;297:
tients with prior myocardial infarction. N Engl J Med 2015;372:17911800.
591602.
187. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi 199.D,Giugliano
Kang TS,RP, ParkWhite
BE, JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van t
Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y. A new Hofstrategy
A, Berdan forLG, dis-Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F,
continuation of dual antiplatelet therapy: the RESET trial (real
Braunwald
safety and E, Harrington
efcacy RA, Califf RM, Newby LK. Early versus delayed, provi-
of3-monthdualantiplatelettherapyfollowingendeavorzotarolimus-elutingstent
sional eptibatide in acute coronary syndromes. N Engl J Med 2009;360:
implantation). J Am Coll Cardiol 2012;60:13401348. 21762190.
188. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, 200.
Botelho
Wang RV,TY,King
WhiteSB 3rd,
JA, Tricoci P, Giugliano RP, Zeymer U, Harrington RA,
Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello
Montalescot HJ Jr, G, James SK, Van de Werf F, Armstrong PW, Braunwald E,
Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori DCaliff
Jr, Gusmao
RM, Newby M, LK. Upstream clopidogrel use and the efcacy and safety of
Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL. Three
earlyeptibatide
vs twelve months treatment in patientswith acute coronarysyndrome:an analysis
315a ESC Guidelines
fromtheearlyglycoproteinIIb/IIIainhibitioninpatientswithnon-ST-segmentele-
patients with non-ST-segment elevation acute coronary syndromes managed
vation acute coronary syndrome (early ACS) trial. Circulation 2011;123:722730.
with an intended early invasive strategy: primary results of the SYNERGY rando-
201. Judge HM, Buckland RJ, HolgateCE, Storey RF. Glycoprotein IIb/IIIa
mizedand trial.
P2Y JAMA
12re-2004;292:4554.
ceptor antagonists yield additive inhibition of platelet aggregation,
217. Murphy
granule SA,secre-
Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman SG,
tion, soluble CD40 l release and procoagulant responses. Platelets Mahaffey
2005;16: KW, Cohen M, McCabe CH, Antman EM, Braunwald E. Efcacy and
398407. safety of the low-molecular weight heparin enoxaparin compared with unfractio-
202. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein
natedheparinacrosstheacutecoronarysyndromespectrum:a
H, Graf I, meta-analysis. Eur
Ibrahim M, Pache J, Seyfarth M, Schuhlen H, Dirschinger J, Berger Heart
PB, J 2007;28:20772086.
Schomig A. Abciximab in patients with acute coronary syndromes 218. YusufS,MehtaSR,ChrolaviciusS,AfzalR,PogueJ,GrangerCB,BudajA,PetersRJ,
undergoing
percutaneous coronary intervention after clopidogrel pretreatment: Bassand the ISAR-
JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and en-
REACT 2 randomized trial. JAMA 2006;295:15311538. oxaparin in acute coronary syndromes. N Engl J Med 2006;354:14641476.
203. Jolly SS, Faxon DP, Fox KA, Afzal R, Boden WE, Widimsky P,219.StegStegPG, Valentin
PG, Jolly V, SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, Lopez-Sendon JL,
Budaj A, Granger CB, Joyner CD, Chrolavicius S, Yusuf S, Mehta Budaj
SR. EfcacyA, DiazandR, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Meeks B,
safety of fondaparinux versus enoxaparin in patients with acuteJoynercoronary C, Pogue
syn- J, Yusuf S. Low-dose vs standard-dose unfractionated heparin
dromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines:
for percutaneous
results coronary intervention in acute coronary syndromes treated
fromtheOASIS5(FifthOrganizationtoAssessStrategiesinIschemicSyndromes)
with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA 2010;304:
trial. J Am Coll Cardiol 2009;54:468476. 13391349.
204. White HD, Chew DP, Hoekstra JW, Miller CD, Pollack CV Jr, Feit
220.F,Szummer
Lincoff AM, K, Oldgren J, Lindhagen L, Carrero JJ, Evans M, Spaak J, Edfors R,
Bertrand M, Pocock S, Ware J, Ohman EM, Mehran R, Stone GW. JacobsonSafety and SH,ef-Andell P, Wallentin L, Jernberg T. Association between the use of
cacyofswitchingfromeitherunfractionatedheparinorenoxaparintobivalirudin
fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients
in patients with non-ST-segment elevation acute coronary syndromes with non-ST-segment
managed elevation myocardial infarction. JAMA 2015;313:707716.
with an invasive strategy: results from the ACUITY (Acute Catheterization
221. Stone GW, andWhite HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT,
Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008;51:17341741.
Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ,
205. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses Mehran JW, R, Moses JW. Bivalirudin in patients with acute coronary syndromes
White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier
undergoingAR, percutaneous coronary intervention: a subgroup analysis from the
Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht Acute Catheterization
HJ, and Urgent Intervention Triage strategY (ACUITY) trial.
Hoekstra J, Mehran R, Ohman EM. Bivalirudin for patients with acuteLancet coronary
2007;369:907919.
syndromes. N Engl J Med 2006;355:22032216. 222. Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM,
206. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de White
WerfHD, F, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M,
White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Clayton
LeonardiTC, S, Mehran R, Pocock SJ. Antithrombotic strategies in patients with
Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier acute
A, coronary syndromes undergoing early invasive management: one-year re-
Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukemasults JW, from the ACUITY trial. JAMA 2007;298:24972506.
Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Psterer
223. Kastrati
M, A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz KL,
Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, WhellanPache DJ,J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Schomig A,
WidimskyP,StronyJ,HarringtonRA,MahaffeyKW.Thrombin-receptorantagon-Berger PB, Mehilli J. Abciximab and heparin versus bivalirudin for
ist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:2033.
non-ST-elevation myocardial infarction. N Engl J Med 2011;365:19801989.
207. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, 224.
FishKastrati
MP, FoxA,KA, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, Khattab AA,
Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar
Schulz J, S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA,
TherouxP, WiviottSD, StronyJ,Murphy SA. Vorapaxar inthe secondary DirschingerJ,RichardtG,BergerPB,SchomigA.Bivalirudinversusunfractionated
preven-
tion of atherothrombotic events. N Engl J Med 2012;366:14041413. heparin during percutaneous coronary intervention. N Engl J Med 2008;359:
208. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer 688696.
TJ, Shook TL,
Lapuerta P, Goldsmith MA, Laine L,Scirica BM, Murphy SA, Cannon 225. AlexanderJH,Lopes
CP. Clopido- RD,JamesS, KilaruR,He Y, MohanP,BhattDL, Goodman S,
grel with or without omeprazole in coronary artery disease. N Engl Verheugt
J Med FW,2010; Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De
363:19091917. Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D,
209. Moukarbel GV, Bhatt DL. Antiplatelet therapy and proton pump Leiva-Pons
inhibition: JL,clin-
Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R,
ician update. Circulation 2012;125:375380. White H,Ruda M,GeraldesM,LawrenceJ,HarringtonRA, WallentinL. Apixaban
210. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusufwith antiplatelet
S. Unfractio-therapy after acute coronary syndrome. N Engl J Med 2011;365:
nated heparin and low-molecular-weight heparin in acute coronary 699708.syndrome
without ST elevation: a meta-analysis. Lancet 2000;355:19361942.226. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P,
211. Silvain J, Beygui F, Barthelemy O, Pollack C Jr, Cohen M, ZeymerCohen U, Huber
M, Cook-Bruns
K, N, Fox KA, Goto S, Murphy SA, Plotnikov AN,
Goldstein P, Cayla G, Collet JP, Vicaut E, Montalescot G. EfcacyandSchneider
safetyofD,en- Sun X, Verheugt FW, Gibson CM. Rivaroxaban in patients with a
oxaparin versus unfractionated heparin during percutaneous coronaryrecent acuteinterven-coronary syndrome. N Engl J Med 2012;366:919.
tion: systematic review and meta-analysis. BMJ 2012;344:e553. 227. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the in-
212. Lee MS, Wali AU, Menon V, Berkowitz SD, Thompson TD, Califf cidence
RM, Topol of myocardial
EJ, infarction and death in patients with unstable angina. A
Granger CB, Hochman JS. The determinants of activated partialmeta-analysis.
thromboplastinJAMA 1996;276:811815.
time, relation of activated partial thromboplastin time to clinical
228.outcomes,
Simoons ML, andBobbink IW, Boland J, Gardien M, Klootwijk P, Lensing AW,
optimal dosing regimens for heparin treated patients with acuteRuzyllo
coronary W, syn-
Umans VA, Vahanian A, Van De Werf F, Zeymer U. A dose-nding
dromes: a review of GUSTO-IIb. J Thromb Thrombolysis 2002;14:91101.study of fondaparinux in patients with non-ST-segment elevation acute coronary
213. Hassan WM, Flaker GC, Feutz C, Petroski GF, Smith D. Improved syndromes:
anticoagulation
the pentasaccharide in unstable angina (PENTUA) study. J Am Coll
with a weight-adjusted heparin nomogram in patients with acute Cardiol
coronary2004;43:21832190.
syn-
dromes: a randomized trial. J Thromb Thrombolysis 1995;2:245249.229. Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, Afzal R, Rush B,
214. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski
PetersG, Sotirov
RJ, Natarajan
I, MK, Velianou JL, Goodhart DM, Labinaz M, Tanguay JF,
Thomas D. Percutaneous coronary intervention after subcutaneous Fox KA,enoxaparin
Yusuf S. Randomized, blinded trial comparing fondaparinux with unfrac-
pretreatment in patients with unstable angina pectoris. Circulationtionated
2001;103:
heparin in patients undergoing contemporary percutaneous coronary
658663. intervention:ArixtraStudy inPercutaneouscoronaryIntervention:aRandomized
215. Martin JL, Fry ET, Sanderink GJ, Atherley TH, Guimart CM, Chevalier
Evaluation PJ, (ASPIRE) pilot trial. Circulation 2005;111:13901397.
Ozoux ML, Pensyl CE, Bigonzi F. Reliable anticoagulation with230.enoxaparin
Petersen in JL,
pa-Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG,
tients undergoing percutaneous coronary intervention: the pharmacokinetics
Langer A, Blazing of MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC,
enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 2004;61:163170.
Harrington RA, Ferguson JJ, Braunwald E, Califf RM. Efcacy and bleeding compli-
216. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman cations S, among patients randomized to enoxaparin or unfractionated heparin for
Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW,antithrombin
Avezum A, therapy in non-ST-segment elevation acute coronary syndromes: a
Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, systematic
Gulba DC, overview. JAMA 2004;292:8996.
Guneri S, Gurnkel E, Harrington R, Hochman JS, Kleiman NS, Leon 231. Brener
MB, SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. Relation-
Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, ship between activated clotting time and ischemic or hemorrhagic complications:
Toro-Figueroa L, White H. Enoxaparin vs unfractionated heparin in high-risk
ESC Guidelines 315b
370. Biancari F, Airaksinen KE, Lip GY. Benets and risks of using
andefcacyofdrug-elutingstentsinwomen:apatient-levelpooledanalysisofran-
clopidogrel before
coronary artery bypass surgery: systematic review and meta-analysis
domised trials. of Lancet
rando- 2013;382:18791888.
mized trials and observational studies. J Thorac Cardiovasc
387. Kaiser
Surg 2012;143:
C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B,
665675, e664. Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Psterer M.
371. Nijjer SS, WatsonG,Athanasiou T, Malik IS.Safetyof clopidogrelbeingcontinued
Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med
until the time of coronary artery bypass grafting in patients
2010;363:23102319.
with acute coronary
syndrome: a meta-analysis of 34 studies. Eur Heart J 2011;32:29702988.
388. GreenhalghJ,HockenhullJ,RaoN,DundarY,DicksonRC,BagustA.Drug-eluting
372. MahlaE,SuarezTA,BlidenKP,RehakP,MetzlerH,SequeiraAJ,Cho stents P, versus
SellJ,FanJ,
bare metal stents for angina oracute coronary syndromes. Cochrane
Antonino MJ, Tantry US, Gurbel PA. Platelet function measurement-based
Database Syst Rev strat-2010;5:CD004587
egy to reduce bleeding and waiting time in clopidogrel-treated
389. Kirtane patients
AJ, Gupta
undergo- A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B,
ing coronary artery bypass graft surgery: the timing based Hannan
on platelet
E, Harjaifunction
K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV,
strategy to reduce clopidogrel-associated bleeding related Waksman
to CABGR, (TARGET-
Lansky AJ, Mehran R, Stone GW. Safety and efcacy of drug-eluting
CABG) study. Circulation Cardiovasc Interv 2012;5:261269. and bare metal stents: comprehensive meta-analysis of randomized trials and ob-
373. Rastan AJ, Eckenstein JI, Hentschel B, Funkat AK, Gummertservational
JF, Dollstudies.
N, Walther Circulation
T, 2009;119:31983206.
Falk V, Mohr FW. Emergency coronary artery bypass graft 390.surgery
Moses for JW, acute
Mehran cor-R, Nikolsky E, Lasala JM, Corey W, Albin G, Hirsch C,
onary syndrome: beating heart versus conventional cardioplegic
Leon MB,cardiac Russellarrest
ME, Ellis SG, Stone GW. Outcomes with the paclitaxel-eluting
strategies. Circulation 2006;114:I477485. stent in patients with acute coronary syndromes: analysis from the TAXUS-IV
374. Ben-Gal Y, Moses JW, Mehran R, Lansky AJ, Weisz G, Nikolsky
trial. J AmE, Argenziano
Coll CardiolM, 2005;45:11651171.
Williams MR, Colombo A, Aylward PE, Stone GW. Surgical 391.versus
YanAT, percutaneous
Yan RT, Tan M, FungA, CohenEA, Fitchett DH, Langer A, Goodman SG,
revascularization for multivessel disease in patients with CanadianAcuteCoronarySyndromes1and2RegistryInvestigators.Management
acute coronary syn-
dromes: analysis from the ACUITY (Acute Catheterizationpatterns
and Urgent in relation
Interven- to risk stratication among patients with non-ST elevation
tion Triage strategY) trial. JACC Cardiovasc Interv 2010;3:10591067.
acute coronary syndromes. Arch Intern Med 2007;167:10091016.
375. Harling L, Moscarelli M, Kidher E, Fattouch K, Ashraan392.
H, Athanasiou
Poon S, Goodman T. The ef- SG, Yan RT, Bugiardini R, Bierman AS, Eagle KA, Johnston N,
fect of off-pump coronary artery bypass on mortality after Huynh
acuteT, coronary
Grondinsyn- FR, Schenck-Gustafsson K, Yan AT. Bridging the gender gap:
drome: a meta-analysis. Int J Cardiol 2013;169:339348. insights from a contemporary analysis of sex-related differences in the treatment
376. Stamou SC, Hill PC, Haile E, Prince S, Mack MJ, Corso PJ.andClinical
outcomes outcomesof patients
of with acute coronary syndromes. Am Heart J 2012;163:
nonelective coronary revascularization with and without cardiopulmonary
6673. by-
pass. J Thorac Cardiovasc Surg 2006;131:2833. 393. Canto JG, Rogers WJ, Goldberg RJ, Peterson ED, Wenger NK, Vaccarino V,
377. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth Kiefe J, Brooks
CI, Frederick
MM, PD, Sopko G, Zheng ZJ, Investigators N. Association of age
Carrie D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb and sex WA,withKahler myocardial
J, infarction symptom presentation and in-hospital mortal-
Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez
ity. JAMA 2012;307:813822.
A,
Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ.394.Coronary
Mehilliartery
J, Kastrati
bypass A, Dirschinger J, Pache J, Seyfarth M, Blasini R, Hall D,
surgery compared with percutaneous coronary interventions Neumannfor multivessel
FJ, Schomig dis-A. Sex-based analysis of outcome in patients with acute
ease: acollaborative analysis of individual patient datafrommyocardial
ten randomisedinfarction trials.
treated predominantly with percutaneous coronary inter-
Lancet 2009;373:11901197. vention. JAMA 2002;287:210215.
378. MohrFW,MoriceMC,KappeteinAP,FeldmanTE,StahleE,ColomboA,MackMJ,
395. Alfredsson J, Lindback J, Wallentin L, Swahn E. Similar outcome with an invasive
Holmes DR Jr, Morel MA, Van Dyck N, Houle VM, Dawkins strategy
KD, Serruys in menPW. and women with non-ST-elevation acute coronary syndromes:
Coronary artery bypass graft surgery versus percutaneous from
coronary
the Swedish
intervention
Web-system for Enhancement and Development of Evidence-
inpatientswiththree-vesseldiseaseandleftmaincoronarydisease:5-yearfollow-
based care in Heart disease Evaluated According to Recommended Therapies
up of the randomised, clinical SYNTAX trial. Lancet 2013;381:629638.
(SWEDEHEART). Eur Heart J 2011;32:31283136.
379. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas 396.G, ChewMack DP, M,Juergens
Yang M, C, French J, Parsonage W, Horsfall M, Brieger D, Quinn S. An
Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, examination
Magnuson EA, of clinical intuition in risk assessment among acute coronary syn-
Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousadromes JE, Rankin patients:
J, observations from a prospective multi-center international ob-
Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal servational
S, King S registry.
3rd, Int J Cardiol 2014;171:209216.
Bertrand M, Fuster V. Strategies for multivessel revascularization
397. Gore MO, in patients
Seliger SL, Delippi CR, Nambi V, Christenson RH, Hashim IA,
with diabetes. N Engl J Med 2012;367:23752384. Hoogeveen RC, Ayers CR, Sun W, McGuire DK, Ballantyne CM, de Lemos JA.
380. WindeckerS,KolhP, AlfonsoF, ColletJP,CremerJ,FalkV, FilippatosG,HammC,
Age- and sex-dependent upper reference limits for the high-sensitivity cardiac
Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser
troponin U, Laufer
T assay. G,J Am Coll Cardiol 2014;63:14411448.
Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini
398. Dey GG, S,Taggart
Flather DP, MD, Devlin G, Brieger D, Gurnkel EP, Steg PG, Fitzgerald G,
Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS
Jacksonguidelines
EA, Eagle KA, Global Registry of Acute Coronary Events Investigators.
on myocardial revascularization. Eur Heart J 2014;35:25412619.
Sex-related differences in the presentation, treatment and outcomes among pa-
381. Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, tients
Mehran withR, acute
Dangas coronary
G, syndromes: the Global Registry of Acute Coronary
Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Prognostic valueEvents. of Heart
the SYNTAX2009;95:2026.
score in patients with acute coronary syndromes undergoing
399. Hochman
percutaneous JS, Tamis cor-JE, Thompson TD, Weaver WD, White HD, Van de Werf F,
onaryintervention:analysisfromtheACUITY(AcuteCatheterizationandUrgent
Aylward P, TopolEJ, Califf RM. Sex, clinical presentation, and outcome in patients
Intervention Triage strategY) trial. J Am Coll Cardiol 2011;57:23892397.
withacutecoronarysyndromes.GlobalUseofStrategiestoOpenOccludedCor-
382. HasdaiD,HarringtonRA,HochmanJS,CaliffRM,BattlerA,BoxJW, onaryArteriesinAcuteCoronarySyndromesIIbInvestigators.NEnglJMed1999;
SimoonsML,
Deckers J, TopolEJ, Holmes DR Jr. Platelet glycoprotein IIb/IIIa
341:226232.
blockade and out-
come of cardiogenic shock complicating acute coronary 400.
syndromes
Wiviott SD, without
Cannon per-CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH,
sistent ST-segment elevation. J Am Coll Cardiol 2000;36:685692.
Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA,
383. Holmes DR Jr., Berger PB, Hochman JS, Granger CB, Thompson
Antman EM, TD, Braunwald
Califf RM, E. Differential expression of cardiac biomarkers by gen-
VahanianA,BatesER, TopolEJ. Cardiogenicshock in patientswithder in acuteischemic
patients with unstable angina/non-ST-elevation myocardial infarction: a
syndromes with and without ST-segment elevation. CirculationTACTICS-TIMI
1999;100: 18 (Treat Angina with Aggrastat and determine Cost of Therapy
20672073. with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction
384. Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock.
18) substudy.
Ann InternCirculation
Med 1999;2004;109:580586.
131:4759. 401. Terkelsen CJ, Sorensen JT, Maeng M, Jensen LO, Tilsted HH, Trautner S, Vach W,
385. ThieleH,ZeymerU,NeumannFJ,FerencM,OlbrichHG,HausleiterJ,RichardtG,
Johnsen SP, Thuesen L, Lassen JF. System delayand mortality among patients with
Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht
STEMI treated R, Fuhrmann
with primary
J, percutaneous coronary intervention. JAMA 2010;
Bohm M, Ebelt H, Schneider S, Schuler G, Werdan K. Intraaortic
304:763771.balloon support
for myocardial infarction with cardiogenic shock. N Engl 402.
J MedAlexander
2012;367: KP, Chen AY, Newby LK, Schwartz JB, Redberg RF, Hochman JS,
12871296. Roe MT, Gibler WB, Ohman EM, Peterson ED. Sex differences in major bleeding
386. Stefanini GG, Baber U, Windecker S, Morice MC, Sartoriwith S, Leon
glycoprotein
MB, Stone IIb/IIIa
GW, inhibitors: results from the CRUSADE (Can Rapid risk
Serruys PW, Wijns W, Weisz G, Camenzind E, Steg PG, Smits stratication
PC, Kandzari of Unstable
D, angina patients Suppress ADverse outcomes with Early
Von Birgelen C, Galatius S, Jeger RV, Kimura T, Mikhail GW, implementation
Itchhaporia D,of the ACC/AHA guidelines) initiative. Circulation 2006;114:
Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo13801387.
A, Mehran R. Safety
315g ESC Guidelines
403. Jneid H, Fonarow GC, Cannon CP, Hernandez AF, Palacios 421.
IF, Maree
Ekerstad AO,N, Swahn E, Janzon M, Alfredsson J, Lofmark R, Lindenberger M,
Wells Q, Bozkurt B, Labresh KA, Liang L, Hong Y, Newby LK, Fletcher
CarlssonG, P. Frailty is independentlyassociated with short-term outcomes for eld-
Peterson E, Wexler L. Sex differences in medical care and early erlydeath
patients
afterwithacutenon-ST-segment elevation myocardial infarction. Circulation
myocardial infarction. Circulation 2008;118:28032810. 2011;124:23972404.
404. VaccarinoV,ParsonsL,PetersonED,RogersWJ,KiefeCI,CantoJ.Sexdifferences
422. Giraldez RR, Clare RM, Lopes RD, Dalby AJ, Prabhakaran D, Brogan GX Jr,
in mortality afteracute myocardial infarction: changes from 1994 Giugliano
to 2006.
RP, Arch
JamesIn-SK, Tanguay JF, Pollack CV Jr, Harrington RA, Braunwald E,
tern Med 2009;169:17671774. Newby LK. Prevalence and clinical outcomes of undiagnosed diabetes mellitus
405. Mehilli J, Kastrati A, Bollwein H, Dibra A, Schuhlen H, Dirschinger
and prediabetes
J, Schomigamong A. patients with high-risk non-ST-segment elevation acute
Gender and restenosis after coronary artery stenting. Eur Heart coronary
J 2003;24:
syndrome. Am Heart J 2013;165:918925, e912.
15231530. 423. Conaway DG, OKeefe JH, Reid KJ, Spertus J. Frequency of undiagnosed
406. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky diabetes
K, Diercksmellitus
DB, in patients with acute coronary syndrome. Am J Cardiol 2005;
Brogan GX Jr, Boden WE, Roe MT, Ohman EM, Gibler WB, Newby 96:363365.
LK. Gender
disparities in thediagnosis andtreatmentof non-ST-segment 424.
elevationacute
NorhammarA,TenerzA,NilssonG,HamstenA,EfendicS,Ryden
cor- L,Malmberg K.
onary syndromes: large-scale observations from the CRUSADE Glucose
(Can Rapid
metabolism
risk in patients with acute myocardial infarction and no
stratication of Unstable angina patients Suppress ADverse outcomes
previous withdiagnosis
Early of diabetes mellitus: a prospective study. Lancet 2002;359:
implementation of the American College of Cardiology/American 21402144.
Heart Associ-
ation guidelines) national quality improvementinitiative. J Am425.CollCardiol
Bartnik M,2005;45:
Ryden L, Malmberg K, Ohrvik J, Pyorala K, Standl E, Ferrari R,
832837. Simoons M, Soler-Soler J. Oral glucose tolerance test is needed for appropriate
407. Gale CP, Cattle BA, Woolston A, Baxter PD, West TH, Simms classication
AD, Blaxillof J, glucose regulation in patients with coronary artery disease: a re-
GreenwoodDC, FoxKA, WestRM. Resolvinginequalitiesincare?Reducedmor-
port from the Euro Heart Survey on Diabetes and the Heart. Heart 2007;93:
tality in the elderly after acute coronary syndromes. The myocardial
7277. ischaemia na-
tional audit project 2003-2010. Eur Heart J 2012;33:630639. 426. DotevallA,HasdaiD,WallentinL,BattlerA,RosengrenA.Diabetesmellitus:clin-
408. Bauer T, Koeth O, Junger C, Heer T, Wienbergen H, Gitt A, icalZahn presentation
R, Senges J,and outcome in men and women with acute coronary syn-
ZeymerU.Effectofaninvasivestrategyonin-hospitaloutcomeinelderlypatients
dromes. Data from the Euro Heart Survey ACS. Diabet Med 2005;22:15421550.
with non-ST-elevation myocardial infarction. Eur Heart J 2007;28:28732878.
427. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP,
409. AlexanderKP,NewbyLK,CannonCP,ArmstrongPW,GiblerWB,RichMW,Van Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA
de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz 2007;298:765775.
HM,
Ohman EM. Acute coronary care in the elderly, part I: non-ST-segment-elevation
428. Angiolillo DJ. Antiplatelet therapy in diabetes: efcacy and limitations of current
acute coronary syndromes: a scientic statement for healthcare treatment
professionals
strategies and future directions. Diabetes Care 2009;32:531540.
fromtheAmericanHeartAssociationCouncilonClinicalCardiology: 429. FerreiroJL,
incollabor- Angiolillo DJ. Diabetes and antiplatelet therapy inacute coronarysyn-
ation with the Society of Geriatric Cardiology. Circulation 2007;115:25492569.
drome. Circulation 2011;123:798813.
410. RosengrenA, Wallentin L, Simoons M, GittAK, Behar S, BattlerA,
430. BartnikHasdaiM, D.Malmberg
Age, K, Norhammar A, Tenerz A, Ohrvik J, Ryden L. Newly de-
clinical presentation, and outcome of acute coronarysyndromes tectedabnormalglucosetolerance:animportantpredictoroflong-termoutcome
inthe Euroheart
acute coronary syndrome survey. Eur Heart J 2006;27:789795. after myocardial infarction. Eur Heart J 2004;25:19901997.
411. Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White 431.K, De Montalescot
Caterina R,G. Madonna R, Sourij H, Wascher T. Glycaemic control in acute cor-
Acute coronary syndromes without chest pain, an underdiagnosed onary syndromes:
and under- prognostic value and therapeutic options. Eur Heart J 2010;31:
treated high-risk group: insights fromthe global registry of acute
15571564.
coronaryevents.
Chest 2004;126:461469. 432. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between
412. Reiter M, Twerenbold R, Reichlin T, Haaf P, Peter F, Meissner hyper-
J, Hochholzer
and hypoglycaemia
W, and 2 year all-cause mortality risk in diabetic patients
Stelzig C, Freese M, Heinisch C, Breidthardt T, Freidank H, Winkler
with acute
K, coronary events. Eur Heart J 2005;26:12551261.
CampodarveI,GeaJ,Mueller C. Earlydiagnosis ofacute myocardialinfarctioninthe
433. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C,
elderlyusingmoresensitivecardiactroponinassays.EurHeartJ2011;32:13791389.
Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J,
413. Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA. The global Patrono
registry
C, Seferovic
of acute P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J,
coronary events, 1999 to 2009GRACE. Heart 2010;96:10951101. Valensi P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H,
414. Skolnick AH, Alexander KP, Chen AY, Roe MT, Pollack CV Jr,Dean Ohman V, Erol
EM, C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J,
Rumsfeld JS, Gibler WB, Peterson ED, Cohen DJ. Characteristics, Kolhmanagement,
P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P,
and outcomes of 5,557 patients age e90 years with acute coronary Sirnes PA, syndromes:
Tamargo JL, Torbicki A, Wijns W, Windecker S, De Backer G,
results from the CRUSADE initiative. J Am Coll Cardiol 2007;49:17901797.
Ezquerra EA, Avogaro A, Badimon L, Baranova E, Betteridge J, Ceriello A,
415. Devlin G, Gore JM, Elliott J, Wijesinghe N, Eagle KA, Avezum Funck-Brentano
A, Huang W, C, Gulba DC, Kjekshus JK, Lev E, Mueller C, Neyses L,
Brieger D. Management and 6-month outcomes in elderly and Nilsson
very elderly
PM, Perk pa-J, Reiner Z, Sattar N, Schachinger V, Scheen A, Schirmer H,
tients with high-risk non-ST-elevation acute coronary syndromes: Stromberg
the Global
A, Sudzhaeva S, Viigimaa M, Vlachopoulos C, Xuereb RG. ESC guide-
Registry of Acute Coronary Events. Eur Heart J 2008;29:12751282. lines on diabetes, pre-diabetes, and cardiovascular diseases developed in collab-
416. Malkin CJ, Prakash R, Chew DP. The impact of increased age oration
on outcome
with the from
EASD. a Eur Heart J 2013;34:30353087.
strategy of early invasive management and revascularisation 434.inVerges
patientsB, Avignon
with acute A, Bonnet F, Catargi B, Cattan S, Cosson E, Ducrocq G,
coronarysyndromes: retrospective analysis study fromthe ACACIA Elbaz registry.
M, FredenrichBMJ A, Gourdy P, Henry P, Lairez O, Leguerrier AM,
Open 2012;2:e000540. Monpere C, Moulin P, Verges-Patois B, Roussel R, Steg G, Valensi P. Consensus
417. Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos statement LA, on the care of the hyperglycaemic/diabetic patient during and in the
Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald immediate
E. The effect
follow-up of acute coronary syndrome. Diabetes Metab 2012;38:
of routine, early invasive management on outcome for elderly 113127.
patients with
non-ST-segment elevation acute coronary syndromes. Ann435. InternKappetein
Med 2004; AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW,
141:186195. Dawkins KD, Mack MJ. Treatment of complex coronary artery disease in patients
418. Savonitto S, Cavallini C, Petronio AS, Murena E, Antonicelliwith
R, Sacco
diabetes:
A, 5-year results comparing outcomes of bypass surgery and percu-
Steffenino G, Bonechi F, Mossuti E, Manari A, Tolaro S, Toso A,taneous
Daniotticoronary
A, intervention in the SYNTAX trial. Eur J Cardiothorac Surg 2013;
Piscione F, Morici N, Cesana BM, Jori MC, De Servi S. Early aggressive
43:10061013. versus ini-
tially conservative treatment in elderly patients with non-ST-segment
436. Kapur A, elevation
Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, Baumbach A,
acute coronary syndrome: a randomized controlled trial. JACC Angelini
Cardiovasc G, deInterv
Belder A, Oldroyd KG, Flather M, Roughton M,
2012;5:906916. Nihoyannopoulos P, Bagger JP, Morgan K, Beatt KJ. Randomized comparison of
419. Andreotti F, Rocca B, Husted S, Ajjan RA, Ten Berg J, Cattaneopercutaneous
M, Collet JP, coronary
De intervention with coronary artery bypass grafting in dia-
Caterina R, Fox KA, Halvorsen S, Huber K, Hylek EM, Lip GY, Montalescot
betic patients. G, 1-year results of the CARDIA (Coronary Artery Revascularization
MoraisJ,PatronoC,VerheugtFW,WallentinL,WeissTW,StoreyRF.Antithrom-
in DIAbetes) trial. J Am Coll Cardiol 2010;55:432440.
botictherapyintheelderly:expertpositionpaperoftheEuropeanSocietyofCar-
437. RofM,AngiolilloDJ,KappeteinAP.Currentconceptsoncoronaryrevasculariza-
diology Working Group on Thrombosis. Eur Heart J 2015 Jul 9;tion doi:in10.1093/
diabetic patients. Eur Heart J 2011;32:27482757.
eurheartj/ehv304 [Epub ahead of print]. 438. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW,
420. Alalo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, Goodman
PopmaSG, JJ, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM.
Ferrucci L, Forman DE. Frailty assessment in the cardiovascular Greater
care ofclinical
olderbenet of more intensive oral antiplatelet therapy with prasugrel
adults. J Am Coll Cardiol. 2014;63:74762. inpatientswith diabetes mellitus inthetrialto assessimprovementintherapeutic
ESC Guidelines 315h
475. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley brillationdeveloped
JD, Buller CE, with the special contribution of the European Heart
Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Early revascularization
Rhythm Association. in Eur Heart J 2012;33:27192747.
acute myocardial infarction complicated by cardiogenic shock. 494.SHOCK
Camm investiga-
AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC,
tors. Should we emergently revascularize occluded coronariesAl-Attar
for cardiogenic
N, Hindricks G, Prendergast B, Heidbuchel H, Aleri O, Angelini A,
shock. N Engl J Med 1999;341:625634. Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M,
476. Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward Hohloser
P, ColSH, J, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the
White HD. Early revascularization and long-term survival in cardiogenic
management shockof atrial brillation: the task force for the management of atrial bril-
complicating acute myocardial infarction. JAMA 2006;295:25112515.lationoftheEuropeanSocietyofCardiology(ESC).EurHeartJ2010;31:23692429.
477. Buerke M, Prondzinsky R, Lemm H, Dietz S, Buerke U, Ebelt 495. H,Lippi
Bushnaq
G, Picanza
H, A, Formentini A, Bonfanti L, Cervellin G. The concentration of
Silber RE, Werdan K. Intra-aortic balloon counterpulsation in thetroponin
treatmentI is increased
of in patients with acute-onset atrial brillation. Int J Cardiol
infarction-relatedcardiogenicshockreviewofthecurrentevidence.ArtifOrgans
2014;173:579580.
2012;36:505511. 496. Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, Gersh BJ,
478. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy Mohan TE, P,Davis
HarjolaBR, VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ,
Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer Wallentin
M, Rouleau L. High-sensitivity
J, troponin I for risk assessment in patients with atrial
Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect ofbrillation:
captoprilinsights
on from the Apixaban for Reduction in Stroke and Other
mortalityand morbidity in patients with left ventricular dysfunction
Thromboembolic
after myocar- Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation
dial infarction. Results of the survival and ventricular enlargement
2014;129:625634.
trial. The SAVE
investigators. N Engl J Med 1992;327:669677. 497. HartRG,BenaventeO,McBrideR,PearceLA.Antithrombotictherapytoprevent
479. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni
stroke in patients
AP, with atrial brillation: a meta-analysis. Ann Intern Med 1999;131:
Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger492501. JD, Henis M,
Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, 498.
captopril,
Echt DS,or bothLiebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH,
in myocardial infarction complicated by heart failure, left ventricular
Arensberg dysfunction,
D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW,
or both. N Engl J Med 2003;349:18931906. and the CAST Investigators. Mortality and morbidity in patients receiving encai-
480. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson
nide, ecainide,
B, Ostergren or placebo.
J, The Cardiac Arrhythmia Suppression Trial. N Engl J
Pfeffer MA, Swedberg K. Effects of candesartan in patients with Med chronic
1991;324:781788.
heart fail-
ure and reduced left-ventricular systolic function intolerant499.
to angiotensin-
Younge JO, Nauta ST, Akkerhuis KM, Deckers JW, van Domburg RT. Effect of an-
converting-enzyme inhibitors: the CHARM-Alternative trial. Lancetemiaonshort-andlong-termoutcomeinpatientshospitalizedforacutecoronary
2003;362:
772776. syndromes. Am J Cardiol 2012;109:506510.
481. Effectofenalaprilonsurvivalinpatientswithreducedleftventricularejectionfrac-
500. Bassand JP, Afzal R, Eikelboom J, Wallentin L, Peters R, Budaj A, Fox KA,
tions and congestive heart failure. The SOLVD investigators. NJoyner
Engl JCD, MedChrolavicius
1991; S, Granger CB, Mehta S, Yusuf S. Relationship between
325:293302. baseline haemoglobin and major bleeding complications in acute coronary syn-
482. Dargie HJ. Effect of carvedilol on outcome after myocardial dromes.
infarction Eur in Heart
patients J 2010;31:5058.
with left-ventricular dysfunction: the CAPRICORNrandomised 501.
trial.
ChaseAJ,FretzEB,WarburtonWP,KlinkeWP,CarereRG,PiD,BerryB,HiltonJD.
Lancet 2001;
357:13851390. Association of the arterial access site at angioplasty with transfusion and mortality:
483. CIBIS-II Investigators. The cardiac insufciency bisoprolol study
the IIM.O.R.T.A.L
(CIBIS-II): astudy ran- (Mortality benet Of Reduced Transfusion after percutan-
domised trial. Lancet 1999;353:913. eous coronary intervention via the Arm or Leg). Heart 2008;94:10191025.
484. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi 502.
P, Agostoni
Rouleau JL, P, Biondi-Zoccai GG, de Benedictis ML, Rigattieri S, Turri M, Anselmi M,
TenderaM,CastaigneA,RoeckerEB,Schultz MK,DeMetsDL.Effectofcarvedilol
Vassanelli C, Zardini P, Louvard Y, Hamon M. Radial versus femoral approach for
on survival in severe chronic heart failure. N Engl J Med 2001;344:16511658.
percutaneous coronary diagnostic and interventional procedures; systematic over-
485. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic viewheart
andfailure:
meta-analysis of randomized trials. J Am Coll Cardiol 2004;44:349356.
metoprolol CR/XL randomised intervention trial in congestive 503.heart
McClure
failure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG,
(MERIT-HF). Lancet 1999;353:20012007. Lincoff AM, Deckers J, Diaz R, Karsch KR, Gretler D, Kitt M, Simoons M,
486. FlatherMD,ShibataMC, Coats AJ,VanVeldhuisenDJ, ParkhomenkoA,BorbolaJ,
Topol EJ, Califf RM, Harrington RA. Clinical signicance of thrombocytopenia
Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J,during
Tavazzi a non-ST-elevation
L, acute coronary syndrome. The Platelet Glycoprotein
SpinarovaL, TomanJ,Bohm M,AnkerSD, ThompsonSG, Poole-WilsonPA.Ran-
IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PUR-
domizedtrialtodetermine theeffect ofnebivololonmortalityandcardiovascular
SUIT) trial experience. Circulation 1999;99:28922900.
hospital admission in elderly patients with heart failure (SENIORS).
504. MerliniEur PA,HeartRossiJ M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ,
2005;26:215225. Ardissino D. Thrombocytopenia caused by abciximab or tiroban and its associ-
487. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg ationK, with
Shi H, clinical
Vincent outcome
J, in patients undergoing coronary stenting. Circulation
Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure
2004;109:22032206.
and mild symp-
toms. N Engl J Med 2011;364:1121. 505. Gore JM, Spencer FA, Gurnkel EP, Lopez-Sendon J, Steg PG, Granger CB,
488. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A,FitzGerald
Palensky J,G, Wittes
Agnelli J. G. Thrombocytopenia in patients with an acute coronary
The effect of spironolactone on morbidity and mortality in patients
syndrome with (from
severethe Global Registry of Acute Coronary Events [GRACE]). Am
heart failure. Randomized aldactone evaluation study investigators.
J Cardiol N 2009;103:175180.
Engl J Med
1999;341:709717. 506. Vora AN, Chenier M, Schulte PJ, Goodman S, Peterson ED, Pieper K,
489. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS,Jolicoeur
Daubert ME,Mahaffey
JP, KW,White H, WangTY. Long-term outcomesassociated
Higgins SL, Brown MW, Andrews ML. Prophylactic implantationwith of ahospital
debrillator acquired thrombocytopenia among patients with non-ST-segment
in patients with myocardial infarction and reduced ejection fraction.
elevation N Engl
acute J Med
coronary syndrome. Am Heart J 2014;168:189196, e181.
2002;346:877883. 507. Greinacher A, Selleng K. Thrombocytopenia in the intensive care unit patient.
490. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R,Hematology
Domanski M, Am Soc Hematol Educ Program 2010;2010:135143.
Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing 508. Warkentin
N, TE. Drug-induced immune-mediated thrombocytopeniafrom pur-
Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone
pura to thrombosis.
or an N Engl J Med 2007;356:891893.
implantable cardioverter-debrillator for congestive heart failure.
509. Dasgupta
N Engl J Med H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ.
2005;352:225237. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/
491. Al-Khatib SM, Hellkamp AS, Lee KL, Anderson J, Poole JE, Mark IIIa DB,
receptor
Bardyinhibitors:
GH. a pooled analysis. Am Heart J 2000;140:206211.
Implantable cardioverter debrillator therapy in patients with 510.
priorValgimigli
coronaryM, re-Biondi-Zoccai G, Tebaldi M, vant Hof AW, Campo G, Hamm C, ten
vascularization in the Sudden Cardiac Death in HEart Failure Trial
Berg(SCD-HEFT).
J,BologneseL,Saia F, Danzi GB, BriguoriC,Okmen E,KingSB, Moliterno DJ,
J Cardiovasc Electrophysiol 2008;19:10591065. Topol EJ. Tiroban as adjunctive therapy for acute coronary syndromes and per-
492. Barsheshet A, Goldenberg I, Moss AJ, Huang DT, Zareba W,cutaneous
McNitt S, Klein coronaryHU, intervention: a meta-analysis of randomized trials. Eur Heart J
Guetta V. Effect of elapsed time from coronary revascularization 2010;31:3549.
to implantation
of a cardioverter debrillator on long-term survival in the MADIT-II
511. Tempelhof
trial. MW, Benzuly KH, Fintel D, Krichavsky MZ. Eptibatide-induced
J Cardiovasc Electrophysiol 2011;22:12371242. thrombocytopenia: with thrombosis and disseminated intravascular coagulation
493. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloserimmediately
SH, Hindricks after left
G, main coronary artery percutaneous coronary angioplasty.
Kirchhof P. 2012 focused update of the ESC guidelines for the Tex management
Heart Inst Jof2012;39:8691.
at-
rial brillation: an update of the 2010 ESC guidelines for the management of atrial
ESC Guidelines 315j
512. Arnold DM, Nazi I, Warkentin TE, Smith JW, Toltl LJ, GeorgeKirchhof
JN, Kelton P, JG.
Kjeldsen
Ap- SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM,
proach to the diagnosis and management of drug-induced immune Schmieder thrombocyto-
RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013
penia. Transfus Med Rev 2013;27:137145. ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J
513. McCulloughJ.Overviewofplatelettransfusion.SeminHematol2010;47:235242.
2013;34:21592219.
514. Kelton JG, Arnold DM, Bates SM. Nonheparin anticoagulants534. for Piepoli
heparin-induced
MF, Corra U, Abreu A, Cupples M, Davos C, Doherty P, Hofer S,
thrombocytopenia. N Engl J Med 2013;368:737744. Garcia-PorreroE,RauchB,Vigorito C,VollerH, Schmid JP.Challengesinsecond-
515. Warkentin TE, Kelton JG. Temporal aspects of heparin-inducedary prevention
thrombocyto- of cardiovascular diseases: a review of the current practice. Int J
penia. N Engl J Med 2001;344:12861292. Cardiol 2015;180:114119.
516. PatrignaniP,PatronoC.Cyclooxygenaseinhibitors:frompharmacologytoclinical
535. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary pre-
read-outs. Biochim Biophys Acta 2015;1851:422432. vention programs for patients with coronary artery disease. Ann Intern Med 2005;
517. Patrono C, Baigent C. Nonsteroidal anti-inammatory drugs143:659672.
and the heart. Circu-
lation 2014;129:907916. 536. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessa-
518. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Barontion JA, inBombardier
patients with C, coronary heart disease: a systematic review. JAMA 2003;290:
Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk8697. E, Hawkey C,
Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine537. L, LanasIestra A,JA,Lance
Kromhout
P, D, van der Schouw YT, Grobbee DE, Boshuizen HC, van
Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell
StaverenP, Wilson WA. K,Effect size estimates of lifestyle and dietary changes on all-cause
Wittes J, Baigent C. Vascular and upper gastrointestinal effects
mortality
of non-steroidal
in coronary artery disease patients: a systematic review. Circulation
anti-inammatory drugs: meta-analyses of individual participant 2005;112:924934.
data from rando-
mised trials. Lancet 2013;382:769779. 538. FoxKM; EURopean trialOn reductionof cardiac eventswith Perindopril instable
519. Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti
coronary I, Leslie
Artery K, disease Investigators. Efcacy of perindopril in reduction of car-
Rao-Melacini P, Chrolavicius S, Yang H, Macdonald C, Avezum diovascular
A, Lanthierevents L, among patients with stable coronary artery disease: rando-
Hu W, Yusuf S. Characteristics and short-term prognosis of perioperative
mised, double-blind, myo- placebo-controlled, multicentre trial (the EUROPA study).
cardial infarction in patients undergoing noncardiac surgery:Lancet
a cohort 2003;362:782788.
study. Ann
Intern Med 2011;154:523528. 539. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J,
520. Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger RahnO, KH,Villar
WedelJC, H, Westerling S. Effects of intensive blood-pressure lowering
Wang CY, Garutti RI, Jacka MJ, Sigamani A, Srinathan S, BiccardandBM, low-dose
Chow aspirin
CK, in patients with hypertension: principal results of the Hyper-
Abraham V, Tiboni M, Pettit S, Szczeklik W, Lurati Buse G, Botto
tension F, Guyatt
Optimal G, Treatment (HOT) randomised trial. Lancet 1998;351:17551762.
Heels-Ansdell D, Sessler DI, Thorlund K, Garg AX, Mrkobrada 540. M,UK Thomas
Prospective
S, Diabetes Study Group. Tight blood pressure control and risk of
Rodseth RN, Pearse RM, Thabane L, McQueen MJ, VanHelder macrovascular
T, Bhandari M, and microvascular complications in type 2 diabetes: UKPDS 38.
Bosch J, Kurz A, Polanczyk C, Malaga G, Nagele P, Le ManachBMJ Y, Leuwer
1998;317:703713.
M,
Yusuf S. Association between postoperative troponin levels 541.
andTaylorRS,BrownA,EbrahimS,JolliffeJ,NooraniH,ReesK,SkidmoreB,StoneJA,
30-day mortality
among patients undergoing noncardiac surgery. JAMA 2012;307:22952304.
Thompson DR, Oldridge N. Exercise-based rehabilitation for patients with cor-
521. Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf onary
S. Association
heart disease:
of diet,systematic review and meta-analysis of randomized con-
exercise, and smoking modication with risk of early cardiovascular
trolled eventstrials. Am after
J Med 2004;116:682692.
acute coronary syndromes. Circulation 2010;121:750758.542. TaylorRS, UnalB,Critchley JA,Capewell S. Mortalityreductions inpatients receiv-
522. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, ingBelder
exercise-based
R, Joyal SV, cardiacrehabilitation: how muchcanbeattributedtocardiovas-
Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid cularlowering
risk factor
with improvements?
sta- Eur J Cardiovasc Prev Rehabil 2006;13:369374.
tins after acute coronary syndromes. N Engl J Med 2004;350:14951504.
543. Hammill BG, Curtis LH, Schulman KA, Whellan DJ. Relationship between cardiac
523. A randomized trial of propranolol in patients with acute myocardial
rehabilitation infarction.
and long-term risks of death and myocardial infarction among eld-
I. Mortality results. JAMA 1982;247:17071714. erly Medicare beneciaries. Circulation 2010;121:6370.
524. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex
544. Perk B, Arnold
J, De Backer
JM, G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C,
Moye L, Pfeffer M. Additive benecial effects of beta-blockers Benlian
to angiotensin-P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G,
converting enzyme inhibitors in the Survival and Ventricular Hobbs
Enlargement R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M,
(SAVE) study. J Am Coll Cardiol 1997;29:229236. Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F.
525. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker Europeanguidelinesoncardiovasculardisease
B, Bittman R, Hurley S, prevention inclinicalpractice(ver-
Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker,
sion 2012).
in patients The with
Fifth left
Joint Task Force of the European Society of Cardiology and
ventricular dysfunction after myocardial infarction. N Engl J Med
other2003;348:13091321.
societies on cardiovascular disease prevention in clinical practice (consti-
526. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockadetuted
on mortality
by representatives
among of nine societies and by invited experts). Eur Heart J
high-risk and low-risk patients after myocardial infarction. N 2012;33:16351701.
Engl J Med 1998;339:
489497. 545. Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, Thompson DR,
527. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala
Taylor N,RS.Peto Exercise-based
R, cardiac rehabilitation for coronary heart disease. Co-
Barnes EH, Keech A, Simes J, Collins R. Efcacy and safety of more
chrane intensive
Database low-
Syst Rev 2011;1:CD001800.
ering of LDL cholesterol: a meta-analysis of data from 170,000
546. Janssen
participants V, DeinGucht
26 V, Dusseldorp E, Maes S. Lifestyle modication programmes
randomised trials. Lancet 2010;376:16701681. for patients with coronary heart disease: a systematic review and meta-analysis of
528. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, FruchartrandomizedJC, Gotto controlled
AM, trials. Eur J Prev Cardiol 2013;20:620640.
GretenH,KasteleinJJ,ShepherdJ,WengerNK.Intensivelipidloweringwithatorvas-
547. Zhang Y, Zhang X, Liu L, Zanchetti A. Is a systolic blood pressure target ,140
tatin in patients with stable coronary disease. N Engl J Med 2005;352:14251435.
mmHg indicated in all hypertensives? Subgroup analyses of ndings from the ran-
529. CannonCP,Blazing MA,GiuglianoRP,McCaggA,WhiteJA,TherouxP,DariusH,
domized fever trial. Eur Heart 2011;32:15001508.
Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, 548.
De Poole-Wilson
Lucca P, Im K,PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N,
Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA,Just Braunwald
H, Fox KA, E, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG,
Califf RM. Ezetimibe added to statin therapy after acute coronary
Dart AM, syndromes.
Hildebrandt N P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE,
Engl J Med 2015;372:238797. Seabra-Gomes R, Soler-Soler J, Weber S. Effect of long-acting nifedipine on mor-
530. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.tality
Effects and of cardiovascular
an morbidity in patients with stable angina requiring treat-
angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular
ment (ACTION eventstrial):
in randomised controlled trial. Lancet 2004;364:849857.
high-risk patients. The Heart Outcomes Prevention Evaluation549. Study
Zanchetti Investiga-
A, Grassi G, Mancia G. When should antihypertensive drug treatment
tors. N Engl J Med 2000;342:145153. be initiated and to what levels should systolic blood pressure be lowered? A crit-
531. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H,icalDagenais
reappraisal. G, Sleight
J Hypertens
P, 2009;27:923934.
Anderson C. Telmisartan, ramipril, or both in patients at high
550.risk NallamothuB,FoxKA,KennellyBM,VandeWerfF,GoreJM,StegPG,GrangerCB,
for vascular
events. N Engl J Med 2008;358:15471559. DabbousOH, Kline-RogersE, Eagle KA.Relationship of treatmentdelays and mor-
532. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto talityS,inOhman patients EM,
undergoing brinolysis and primary percutaneous coronary inter-
Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt vention.TheGlobalRegistryofAcuteCoronaryEvents.Heart2007;93:15521555.
DL; Reach
Registry Investigators. Beta-blocker use and clinical outcomes
551. Mukherjee
in stable outpati- D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of
ents with and without coronary artery disease. JAMA 2012;308:13401349.
combination evidence-based medical therapy on mortality in patients with acute
533. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bo coronary
hm M, syndromes.
Christiaens T, Circulation 2004;109:745749.
Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T,